Top

Camilo Jimenez, M.D.

Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine

About Dr. Camilo Jimenez

Dr. Jimenez is a Tenured Professor of Endocrine Neoplasia and Hormonal Disorders at the University of Texas MD Anderson Cancer Center. He is the principal investigator of six clinical trials for patients with metastatic pheochromocytomas and paragangliomas. His research led to the identification of high-specific activity MIBG as an effective medication for metastatic pheochromocytomas and paragangliomas; this medication became the first FDA-approved medication in the United States for this indication. Dr. Jimenez has performed extensive clinical research in the field of endocrine cancer with a particular interest in pheochromocytomas and paragangliomas. Dr. Jimenez was one of the first clinicians to describe the use of tyrosine kinase inhibitors in patients affected with sporadic and hereditary (Von Hippel-Lindau and Paraganglioma syndrome type 4) metastatic pheochromocytomas and sympathetic paragangliomas. His observations led to the development of clinical trials with tyrosine kinase inhibitors including the phase 2 clinical trial with Cabozantinib (NATALIE Trial) which reported that Cabozantinib is an effective treatment for the disease. This work was published in the Lancet Oncology in 2024 and was recognized with the award “the Manuscript of the Year” by the Division of Internal Medicine. Dr. Jimenez is the leading worldwide principal investigator of the phase 2 clinical trial with Belzutifan for patients with metastatic pheochromocytoma and paraganglioma. The results of this trial are impressive; the medication is now under priority review by the FDA, and Dr. Jimenez will present the final results at ESMO in Berlin, Germany in October 2025. Dr. Jimenez also characterized inherent complications related to excessive hormonal secretion and tumor burden distinctive of this disease. His seminal accomplishments include assessing the value of antiresortive agents and chemotherapy against bone metastases; demonstrating that systemic chemotherapy with cyclophosphamide, vincristine, and dacarbazine is associated with improved overall survival; describing the clinical predictors of aggressiveness and overall survival of these tumors, the value of surgery in patients with metastatic disease, and the managing of gastrointestinal and cardiovascular complications.

Dr. Jimenez has published 150 manuscripts in high-impact journals such as the Lancet Oncology, Nature Reviews in Endocrinology, Annals of Surgery, Clinical Nuclear Medicine, and the Journal of Nuclear Medicine and chapters for prestigious books, including Harrison’s Principles of Internal Medicine. He was a member of the editorial board for the Journal of Clinical Endocrinology and Metabolism. Dr. Jimenez presented at the Schimke Memorial Lecture Grand Rounds at the University of Kansas and has been invited to give lectures for Grand Rounds at several other institutions in the US, Canada, Australia, Europe, Japan, South America, and Africa. Dr. Jimenez has lectured in many national and international scientific meetings and he was the co-chair of the International Society for Pheochromocytoma and Paraganglioma Research PRESSOR. He was recognized by the PheoPara Alliance because of his contributions to the field with the 2015 Science Award. Dr. Jimenez was the Chair of the Diversity and Membership Committee of the North American Neuroendocrine Tumor Society NANETS. His very focused and successful career has positioned him as an example to be followed by the new generations of endocrinologists. Emblematic of this success, the Endocrine Society invited him, four years in succession, to give the honorary lecture titled “How I got here? A personal journey.”

Primary Appointment

Professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

Pheochromocytomas, Paragangliomas, Multiple Endocrine Neoplasias, Medullary Thyroid Cancer, Endocrine Sequelae of Cancer Therapies

Clinical Interests

Pheochromocytomas, Paragangliomas, Multiple Endocrine Neoplasias, Medullary Thyroid Cancer, Endocrine Sequelae of Cancer Therapies

For general clinic information and referrals, please visit the Department of Endocrine Neoplasia and Hormonal Disorders' contact information webpage at:

Contact Information

Education & Training

Degree-Granting Education

1995	Pontificia Universidad Javeriana, Santa Fe de Bogota, CO, MD

Postgraduate Training

2001-2004	Clinical Fellowship, Endocrinology, Diabetes and Metabolism, Baylor College of Medicine and The University of Texas MD Anderson Cancer Center, Houston, Texas
1999-2001	Clinical Residency, Internal Medicine, The University of Miami Jackson Memorial Hospital, Miami, Florida
1998-1999	Clinical Internship, Internal Medicine, The University of Miami Jackson Memorial Hospital, Miami, Florida
1996-1998	Clinical Residency, Internal Medicine, The National Cancer Institute, Santa Fe de Bogota

Licenses & Certifications

2007	Texas Medical License
2006	Endocrinology, Diabetes and Metabolism
1997	Colombia Medical License

Experience & Service

Faculty Academic Appointments

Associate Professor, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2017

Assistant Professor, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, 2006 - 2012

Other Professional Positions

Member of the Medical Advisory Board, Lantheus, Houston, TX, 2021 - Present

Chair of the Pheochromocytoma Paraganglioma TNM Staging Group, American Joint Commission for Cancer, Houston, TX, 2021 - Present

Panel Member, American Association of Endocrine Surgeons Guidelines on Adrenal Tumors, Houston, TX, 2021 - Present

Chair, North American Neuroendocrine Tumor Society Guidelines Panel for Metastatic Pheochromocytoma and Paraganglioma, Houston, TX, 2020 - Present

Medical Advisor Board Member, Pheo Para Alliance, Houston, TX, 2020 - Present

Member of the Medical Advisory Board, Merck, Houston, TX, 2020 - Present

Member of the Medical Advisory Board, HRA Pharma, Houston, TX, 2020 - Present

Chair, Diversity Inclusion and Equity Membership Committee of North American Neuroendocrine Tumor Society, Houston, TX, 2020 - 2023

Committee Member, Pituitary, Gonad, Adrenal and Neuroendocrine Disease State Network Committee, American Association of Clinical Endocrinology (AACE), 2019 - 2020

Member of the Adrenal Board, American Association of Clinical Endocrinologist, Jacksonville, FL, 2017 - 2018

Chair, International Society for Pheochromocytoma and Paraganglioma Research Support PRESSOR, Houston, TX, 2012 - 2015

Member, External Advisory Board, The University of Pennsylvania, Philadelphia, PA, 2012 - Present

Intramural Institutional Committee Activities

Member, Workforce Community and Connections, The University of Texas MD Anderson Cancer Center, 2024 - Present

Member, Radiation Safety, The University of Texas MD Anderson Cancer Center, 2024 - Present

Diversity Leader, Faculty Diversity, Equity and Inclusion, The University of Texas MD Anderson Cancer Center, 2021 - 2023

Member, International Advisory Board, The University of Texas MD Anderson Cancer Center, 2015 - Present

Member - Referee, Faculty Academic Review Committee, The University of Texas MD Anderson Cancer Center, 2015 - Present

Member, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2014 - Present

Alternate Member, Credentials Committee of the Medical Staff, The University of Texas MD Anderson Cancer Center, 2013 - 2016

Program Co-Chair, Multidisciplinary Parathyroid Conference, The University of Texas MD Anderson Cancer Center, 2011 - 2014

Member, Chemistry Faculty Position Search Committee, Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, 2010 - 2011

Member, Annual Review of Cancer Survivorship Algorithm: Gynecologic Cancer Survivorship - Bone Health, The University of Texas MD Anderson Cancer Center, 2010 - Present

Member, Division of Internal Medicine Research Committee, The University of Texas MD Anderson Cancer Center, 2010 - 2012

Member, IMC Steering Committee, The University of Texas MD Anderson Cancer Center, 2007 - 2010

Member, Clinical Research 3 Committee, The University of Texas MD Anderson Cancer Center, 2007 - 2010

Extramural Institutional Committee Activities

AJCC Expert Panel Member, American College of Surgeons (ACS), American College of Surgeons, 2025 - Present

Editorial Activities

Review Editor, Frontiers in Endocrinology and Frontiers in Oncology, 2020 - Present

Editorial Board member, Journal Cancers, 2019 - Present

Editorial Board Member, The Journal of Clinical Endocrinology and Metabolism, 2010 - 2014

Honors & Awards

2026	2026 Top Doctor, Caste Connolly Top Doctor
2025 - Present	Scientist of the Year, Pheo Para Alliance
2025	2025 Top Doctor, Castle Connolly Top Doctor
2024 - Present	PRS Top Performer, PRS Annual Business Meeting/ PRS Administrative Services
2024	Distinguished Paper Award in Clinical Science, January - June 2024, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center
2019	Wall of Science, MD Anderson, The University of Texas MD Anderson Cancer Center
2019 - 2020	Committee Member Recognition, Pituitary, Gonad, Adrenal and Neuroendocrine Disease State Network Committee, American Association of Clinical Endocrinology (AACE)
2018 - 2023	Top 1% Provider, MD Anderson, Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CGCAHPS)
2018	Nomination for the 2018 Division Faculty Excellence Award in Research, University of Texas MD Anderson Cancer Center
2016	Best Teacher Award, Baylor College of Medicine Fellowship Program
2015	Pheo Para Alliance Science Award, Pheo Para Alliance
2014	Thyroid Cover Credit, American Thyroid Association
2014	Faculty Leadership Academy, MD Anderson Cancer Center
2013	Presidential Poster Winner: Adrenal Ganglioneuroma: 20-year experience in a tertiary referral cancer center, Endocrine Society
2012	Faculty of 1000 Recommended Article, Faculty of 1000 Research
2011	Presidential Poster Award: Clinical Benefits of Chemotherapy in Patients with Metastatic Pheochromocytomas and Sympathetic Paragangliomas: Review of the Largest Single-Institution Experience, ENDO Society
2011	Nature Reviews Endocrinology 2011 Cover Competition Winner - Adrenal Cortical Carcinoma, Nature Reviews Endocrinology
2011	Presidential Poster Award: Experience with the Tyrosine Kinase Inhibitor Sunitinib in Metastatic Pheochromocytomas and Paragangliomas, ENDO Society
2011	Ten Best Readings Relating to Endocrine Cancer - Clinical Risk Factors for Malignancy and Overall Survival in Patients with Pheochromocytomas and Sympathetic Paragangliomas: Primary Tumor Size and Primary Tumor Location as Prognostic Indicators Article, Cancer Control, Journal of the Moffitt Cancer Center
2009	Journal of Clinical Endocrinology and Metabolism Cover of the Month Metastatic Pheochromocytoma Responding to Sunitinib, The Endocrine Society
2007	Outstanding Clinical Research Committee Reviewers, The University of Texas M. D. Anderson Cancer Center
2007	Excellence in Teaching Award, Baylor College of Medicine/The University of Texas M.D. Anderson Cancer Center
2007	Apple Award/Outstanding Patient Educator Award, The University of Texas M. D. Anderson Cancer Center
2006	First Award as the most productive researcher, Santa Fe Foundation and The University of the Andes
2006	The Best of Endocrinology for Latin America, Cartagena de Indias
2005	Nominated as the Best First Author Clinical Investigator of 2005 - Primary Hyperparathyroidism and Osteosarcoma: Examination of a Large Osteosarcoma Cohort Identifies Unique Characteristics, The American Society of Bone and Mineral Research, ASBMR
2005	First Award as the Most Productive Researcher of the Santa fé Foundation and The University of the Andes, Santa Fé Foundation and The University of the Andes
2004	Parathyroid Carcinoma, Two Decades of Experience, Annual Trainee Research Award, Second Best Clinical Research Project, Baylor College of Medicine and The University of Texas M. D. Anderson Cancer
2004	Genentech Clinical Fellow Travel Grant, 86th Annual Meeting of the American Endocrine Society
2003	Resident and Staff Physician Fellow Correspondent Program, One of eight fellows chosen to represent the U.S. at the 2003 meeting, International Diabetes Federation, Paris, France
2003	The Endocrine Society Student Affairs Committee Travel Grant for one of the top five fellows in Endocrinology in the US on Growth Hormone Research, Endocrine Society - Sahlgrenska Hospital, Gothenburg, Sweden
2002	Best Postgraduate Clinical Research Project, University of Miami, Jackson Memorial Hospital, and The Miami Veterans Administration Hospital, University of Miami School of Medicine
2001	Vitamin D Deficiency in Miami, Florida, Best Clinical Research Project, Department of Internal Medicine, The Jackson Memorial Hospital and The Miami Veterans Administration Hospital, The University of Miami
2001	Recognition of Excellence in Achievement and Outstanding Presentation, Resident Scholarly Activity Program, Best Clinical Researcher Vitamin D Deficiency in South Florida, The Jackson Memorial Hospital and The Miami Veterans Administration Hospital, The University of Miami
2000	Best In-training Exam, Internal Medicine Residency Program, University of Miami
1995	One of the Top Five Medical Students Graduated in Colombia amongst 1406 Graduates, Colombian Association of Medical Schools
1994	One of the top three medical students, Javeriana University
1994	Best Intern, National Police Central Hospital
1990	Honors in Pathology, Javeriana University
1990	Honors in Physiology, Javeriana University
1990	Honors in Biochemistry, Javeriana University

Professional Memberships

The North American Neuroendocrine Tumor Society

2018 - Present

American Association of Clinical Endocrinology

2017 - Present

PRESSOR Society

2008 - Present

The Colombian Endocrine Society

2004 - Present

The American Diabetes Association

2004 - 2008

The International Pituitary Society

2002 - 2007

Selected Presentations & Talks

Local Presentations

2026. From Mutation to Medication. Invited. Clinical Cancer Genetics Grand Rounds. Houston, Texas, US.
2025. Pheochromocytoma/Paraganglioma. Invited. Harris Health Smith Clinic. Houston, Texas, US.
2018. An update on malignant pheochromocytoma/paraganglioma, including the use of radiopharmaceuticals. Invited. Pediatric Grand Rounds. Houston, TX, US.
2017. Management of Phaeochromocytoma and Paraganglioma. Invited. Houston, TX, US.
2016. Management of Locally Advanced and Metastatic Neuroendocrine Tumors: Pheochromocytoma and Paraganglioma. Invited. 11th Urologic Oncology Advances in Clinical Practice. Houston, TX, US.
2008. Pheochromocytomas in von Hippel Lindau Disease. Invited. VHL Family Alliance Meeting. Houston, TX, US.
2007. Osteoporosis in Breast and Prostate Cancer Survivors. Invited. Anderson Network 19th Annual Living Fully With and Beyond Cancer Patient and Caregiver Conference. Houston, TX, US.
2004. Hereditary Pheochromocytomas. Invited. The Veterans Administration Hospital, Baylor College of Medicine. Houston, TX, US.
2003. Acromegaly: The Fire’s Last Chance. Invited. The Veterans Administration Hospital, Baylor College of Medicine. Houston, TX, US.
2003. Growth Hormone, Insulin like Growth Factors and Insulin like Growth Factor Binding Proteins: Is this the most complex endocrine system?. Invited. Baylor College of Medicine. Houston, TX, US.
2003. Phosphate metabolism: Tumoral Induced Osteomalacia, Fanconi Syndrome and Other Disorders. Invited. The Veterans Administration Hospital, Baylor College of Medicine. Houston, TX, US.
2002. Diagnosis and Treatment of the Diabetic Foot. Invited. 4th Annual, Patient and Family Diabetes Workshop. Houston, TX, US.
2002. Primary Hyperparathyroidism and the Calcium Sensing Receptor. Invited. The Veterans Administration Hospital. Houston, TX, US.
2002. Endocrine Complications of Histiocytosis X: Panhypopituitarism, Central Diabetes Insipidus, and Bone Disease. Invited. Texas Children’s Hospital, Texas Heart Institute, Baylor College of Medicine. Houston, TX, US.
2002. Disorders of Mineral Metabolism. Invited. Osteoporosis, Parathyroid Diseases and other disorders of Mineral Metabolism. Houston, TX, US.
2002. Humoral Hypercalcemia of Malignancy. Invited. The Veterans Administration Hospital. Houston, TX, US.
2001. Osteoporosis. Invited. Glucocorticoid Induced Osteoporosis. Houston, TX, US.
2001. Insulin Resistance/Insulin Receptor. Invited. The Veterans Administration Hospital, Baylor College of Medicine. Houston, TX, US.

Regional Presentations

2025. 177Lu-DOTATATE for the Treatment of Metastatic Pheochromocytoma and Paraganglioma. Conference. 2025 World Molecular Imaging Congress, Alaska, US.
2017. Phaeochromocytoma and Paraganglioma: New Horizons Grand Rounds. Invited. University of Texas San Antonio. San Antonio, TX, US.
2009. An Update on Imaging in Pheochromocytoma. Invited. American Association of Clinical Endocrinology (AACE). Austin, TX, US.
2007. Evaluation of Patients with Hypercalcemia. Invited. 2nd Current Concepts in the Management of Thyroid and Parathyroid Neoplasms. Santa Fe, NM, US.
2007. Osteoporosis Update. Invited. TAFP. Corpus Christi, TX, US.

National Presentations

2026. Endocrine Grand Rounds. Invited. Endocrine Grand Rounds Brown University. Providence, RI, US.
2025. NANETS PODCAST SERIES | December Edition: Pheochromocytoma & Paraganglioma. Invited. Houston, Texas, US.
2025. Patient Ed Webinar: Belzutifan. Invited. Pheo Para Alliance (PPA) Webinar. Houston, Texas, US.
2025. 177Lu-DOTATATE for the Treatment of Metastatic Pheochromocytoma and Paraganglioma. Poster. 2025 World Molecular Imaging Congress. Anchorage, Alaska, US.
2025. Management of Metastatic Pheochromocytomas and Paragangliomas (PPGL). Invited. Endocrine Society's Annual Meeting, ENDO 2025. San Francisco, Califonia, US.
2025. Medical Therapy for Somatotroph Pituitary Tumors. Invited. NASBS 2025 Annual Meeting. New Orleans, Louisiana, US.
2025. Systemic Therapy For Head And Neck Paragangliomas. Invited. 34th North American Skull Base Society (NASBS) and 9th World Federation of Skull Base Societies (WFSBS) joint meeting. New Orleans, Louisiana, US.
2024. Pheochromocytomas, Paragangliomas or Multiple Endocrine Neoplasia. Invited. WSU/DMC Endocrinology Grand Round - Teleconference, US.
2024. Multikinase Inhibitors / Drug development. Invited. ENETS-NANETS Webinar, US.
2024. Systemic Therapy for Metastatic Pheochromocytoma and Paraganglioma: Lessons Learned from Clinical Trials and Real-World Studies. Invited. IAM- International Adrenal Meeting. Boston, MA, US.
2024. Treatment for patients with pheochromocytomas and paragangliomas: New perspectives, New Horizons. Invited. University of Connecticut. Farmington, CT, US.
2024. Paraganglioma Syndromes and Chemotherapy and Targeted Therapy for Paraganglioma. Invited. NASBS 33rd Annual Meeting. Atlanta, GA, US.
2023. Rare NET Tumor Updates: Pheo/Para. Invited. Virtual Conference, US.
2022. Pheochromocytoma and Paraganglioma. Invited. NANETS - North American Neuroendocrine Tumor Society. Houston, TX, US.
2021. Consensus Guidelines on the Management of Pheochromocytoma/Paraganglioma. Invited. NANETS NET Medical Symposium 2021. Chicago, IL, US.
2021. Treatment of metastatic Pheochromocytoma/Paraganglioma. Invited. NANETS. Chicago, IL, US.
2021. Radioligand Therapy and Treatment Sequencing for Metastatic and Unresectable Pheochromocytomas and Paragangliomas. Invited. NANETS. Chicago, IL, US.
2021. Treatment of Metastatic Pheochromocytoma. Invited. New England Fellows Didactic Series. Boston, MA, US.
2021. Immunotherapy: Does It Work?. Invited. ENDO 2021. San Francisco, CA, US.
2021. Biochemical Tumor Marker Status and Its Role in Treatment Response in Patients Who Received High-Specific-Activity I-131 MIBG in Advanced Pheochromocytoma and Paraganglioma (PPGL): Results from a Pivotal Phase 2 Clinical Trial. Invited. ENDO 2021. San Francisco, CA, US.
2021. Management of Endocrine Complications of Pheochromocytoma and Paraganglioma: From Cardiovascular to Gastrointestinal Disease. Invited. University of Kansas Distinguished Faculty for the R. Neil Schimke, MD Memorial Lecture 2021. Wichita, Kansas, US.
2020. Incorporating New Approaches for Diagnosis and Treatment of Neuroendocrine Tumors: Endocrinologist Perspective. Invited. SNMMI. Washington, DC, US.
2020. Updated Long-Term Survival and Safety from a Multi-Center, Open-label, Pivotal Phase 2 Study of AZEDRA® In Patients with Unresectable, Locally Advance or Metastatic Pheochromocytoma or Paraganglioma. Invited. American Urological Association. Washington, DC, US.
2020. Laboratory testing in pheochromocytoma and paraganglioma. Invited. AACE. Washington, DC, US.
2019. Redifferentiation Radioiodine (RAI)-Therapy in Patients (PTS) with Metastatic Papillary, Follicular and Poorly Differentiated Thyroid Cancer (TC). Invited. 89th Annual American Thyroid Association Conference. Chicago, IL, US.
2019. Control of Hormonal Syndromes for Pheochromocytoma and Paraganglioma. Invited. NANETS - North American Neuroendocrine Tumor Society. Boston, MA, US.
2019. I-131 MIBG for Advanced Pheochromocytoma and Paraganglioma. Invited. 2019 SNMMI Conference. Anaheim, CA, US.
2019. Malignant Pheochromocytoma/Paraganglioma - Grand Rounds. Invited. University of California, San Diego. San Diego, CA, US.
2019. Pheochromocytoma Management. Invited. 28th Annual Scientific & Clinical Conference. Los Angeles, CA, US.
2019. Meet the Professor on Pheochromocytoma Perioperative Management and Imaging Status. Invited. ENDO 2019. New Orleans, LA, US.
2019. Safety Analysis of High-Specific-Activity I-131 MIBG (AZEDRA®) in Patients with Iobenguane Scan Positive Cancers. Invited. ENDO 2019. New Orleans, LA, US.
2019. Overview of Thyroid Cancer. Current Management, New Therapies, New Guidelines. Invited. ARGONNE/IAEA-Regional Training Course on Targeted Radionuclide Therapy. Houston, TX, US.
2019. I131 Iobenguane for Radionuclide Therapy of Pheochromocytoma/Paraganglioma. Invited. 2019 SNMMI Mid-Winter and ACNM Conference. Palm Springs, CA, US.
2018. A Phase 2 Study to Evaluate The Effects of Cabozantinib in Patients with Unresectable Metastatic Pheochromocytomas and Paragangliomas. Invited. AACE 2018. Boston, MA, US.
2018. AZEDRA® (iobenguane I 131) In Patients With Metastatic And/or Recurrent And/or Unresectable Pheochromocytoma Or Paraganglioma: Biochemical Tumor Marker Results Of A Multicenter, Open-label Pivotal Phase 2b Study. Invited. ENDO 2018. Chicago, IL, US.
2017. Pheochromocytoma: Pathogenesis, Chemotherapy, and Targeted Therapies. Invited. 10th annual NANETS Neuroendocrine Tumor Symposium. Philadelphia, PA, US.
2017. AZEDRA® (iobenguane I 131) in Patients with Malignant and/or Recurrent Pheochromocytoma/ Paraganglioma (PPGL): Final Results of a Multi-Center, Open-Label, Pivotal Phase 2b Study. Invited. 10th annual NANETS Neuroendocrine Tumor Symposium. Philadelphia, PA, US.
2017. Ultratrace® Iobenguane I-131 (AZEDRATM) in Patients with Malignant or Recurrent Pheochromocytoma / Paraganglioma. Invited. Symposium on Developments for Rare Endocrine Cancers. New York, NY, US.
2017. A Phase 2 Study to Evaluate the Effects of Cabozantinib in Patients with unresectable Metastatic Pheochromocytomas and Paragangliomas. Invited. Global Academic Programs Symposium. Houston, TX, US.
2016. Effectiveness of First-Line Pegvisomant Monotherapy in Acromegaly; an Acrostudy Analysis. Invited. ENDO 2016. Boston, MA, US.
2016. Medullary Thyroid Cancer with Bone Metastases and the Effect of Antiresorptive Agents on Skeletal Related Events. Invited. ENDO 2016. Boston, MA, US.
2015. Endocrine Grand Rounds: Pheochromocytoma and Sympathetic Paraganglioma: Progress on Therapeutics. Invited. Memorial Sloan-Kettering Cancer Center. New York, NY, US.
2015. Fungal infections mimicking Metastatic Differentiated Thyroid Cancer. Invited. AACE 2015 Annual Meeting. Nashville, TN, US.
2015. Long Term Follow-up of a Pivotal Phase 2 Study of Ultratrace® Iobenguane I-131 (AZEDRATM) in Patients with Malignant Relapsed/Refractory Pheochromocytoma (Pheo)/Paraganglioma (Para). Invited. ENDO 2015. San Diego, CA, US.
2015. Pheochromocytomas and Sympathetic Paragangliomas: Focus on Therapeutics. Invited. ENDO 2015. San Diego, CA, US.
2015. How I Got Here: A Personal Journey. Invited. ENDO 2015. San Diego, CA, US.
2015. Endocrine Grand Rounds. Invited. University of Miami. Miami, FL, US.
2014. How Did I Get Here? A Personal Journey. Invited. ENDO 2014: The 96th Annual Meeting and Expo. Chicago, IL, US.
2014. Careers in Research. Invited. The Latino Medical Student Association. Miami, FL, US.
2013. How Did I Get Here? A Personal Journey. Invited. ENDO 2013: The 95th Annual Meeting and Expo. San Francisco, CA, US.
2012. Hyperparathyroidism. Invited. ENDO 2012: The 94th Annual Meeting and Expo. Houston, TX, US.
2012. How Did I Get Here? A Personal Journey. Invited. ENDO 2012. Houston, TX, US.
2011. Genetics, Screening, Evaluation and Treatment of Medullary Thyroid Cancer. Invited. 4th Annual Current Concepts in the Management of Thyroid and Parathyroid Neoplasms. Santa Fe, NM, US.
2011. Genetic Testing in Head and Neck Paragangliomas: Who, What and Why?. Invited. American Academy of Otolaryngology - Head and Neck Surgery Foundation. San Francisco, CA, US.
2011. Increased Bone Mineral Density in the Setting of Hypocalcemia. Invited. Santa Fe Bone Symposium. Santa Fe, NM, US.
2011. Pheochromocytoma and Paraganglioma Syndromes: What's New?. Invited. ENDO 2011: The 93rd Annual Meeting & Expo. Boston, MA, US.
2010. Clinical Risk Factors for Malignancy in Pheochromocytomas and Paragangliomas. Invited. The Endocrine Society's 92nd Annual Meeting and Expo. San Diego, CA, US.
2009. Sunitinib Versus Sorafenib in Malignant Pheochromocytoma. Invited. Second Malignant Pheochromocytoma Expert Group (MPGE). New York City, NY, US.
2009. Follow-up of Pituitary Volumes in Patients with Acromegaly Treated with Pegvisomant. Invited. KIMS/KIGS International Meeting. Fort Lauderdale, FL, US.
2009. Bone Mineral Density in Patients with Acromegaly Treated with Pegvisomant. Invited. KIMS/KIGS International Conference. Fort Lauderdale, FL, US.
2007. RET Proto-Oncogene: an Example of a Genotype-Phenotype Correlation. Invited. Harrington Program 40th Anniversary. Miami, FL, US.
2003. Parathyroid Carcinoma Two Decades of Experience Research at MD Anderson Conference. Invited. Columbia University. New York, NY, US.

International Presentations

2026. From Mutation to Medication: The Genetic Roadmap in Pheochromocytoma Treatment. Invited. ENS@T Webinar 2026: Genetic Breakthroughs in Adrenal Tumours: Unveiling the Latest Advances.
2026. ENETS Webinar: Advances in Pheochromocytomas and Paragangliomas (PPGL). Invited. Berlin, DE.
2025. xxxxx. Invited. Vizcaya, ES.
2025. LITESPARK-015: Belzutifan in advanced pheochromocytoma and paraganglioma. Invited. ESMO 2025. Berlin, ES.
2025. Integrating Tumor Biology and Clinical Practice: Game Changer for Precision Medicine of Patients with Pheochrocytoma and Paraganglioma. Invited. 7th International Symposium on Pheochromocytoma (ISP). Montreal, CA.
2025. Systemic treatment of metastatic pheochromocytomas and paragangliomas. Invited. 19th International Workshop on Multiple Endocrine Neoplasia and other rare endocrine tumors in Sao Paulo. Sao Paulo, BR.
2025. Institutional Grand Rounds on the progress made on systemic therapies against malignant pheochromocytoma. Visiting. National Cancer Institute in Rio de Janeiro. Rio de Janeiro, BR.
2025. Masas Adrenales: ¿Cuáles Operar y Cuales Observar?. Invited. 18th ENDOCONGRESS. Medellin, CO.
2025. Feocromocitomas y Paragangliomas. Invited. 18th ENDOCONGRESS. Medellin, CO.
2024. Consensus on the Methodology of Trials in an Ultrarare Cancer : Malignant Pheochromocytoma and Paraganglioma. Invited. 23rd edition of the ENS@T Scientific Meeting and the 3rd COST Harmoniz@tion meeting. Palma de Mallorca, ES.
2024. Highlights of PRRT and drug development abstracts. Invited. ENETS-NANETS webinar, US.
2024. Masas adrenales: Cuales operar y cuales observar. Invited. X ENDIMET - Curso Internacional de Endocrinología Diabetes y Metabolismo. Cartagena, CO.
2023. EO2401 peptide immunotherapy + nivolumab in adrenocortical carcinoma (ACC);-the Phase 1/2 EOADR1-19/SPENCER trial. Invited. European Network for the Study of Adrenal Tumors, HR.
2023. EO2401 peptide immunotherapy + nivolumabin metastatic pheochromocytoma / paraganglioma (MPP);-the Phase 1/2 EOADR1-19/SPENCER trial. Invited. European Network for the Study of Adrenal Tumors. Dubrovnik, HR.
2023. A phase 2 clinical trial of cabozantinib in patients with unresectable and progressive metastatic pheochromocytoma or paraganglioma: The NATALIE trial. Invited. NANETS. Montreal, CA.
2023. Advances in Pheochromocytomas and Paragangliomas: New Horizons, Ne Therapies. Invited. Colombian Association of Endocrinology, Diabetes and Metabolism. Bogota, CO.
2023. Recent advances in therapies targeting endocrine malignancies. Invited. European Society of Endocrinology. Istanbul, US.
2023. RETi in MEN2. Invited. WorldMEN. Marseille, FR.
2022. Clinical trials for metastatic pheochromocytoma and paraganglioma: New horizons, new perspectives. Invited. 6th International Symposium on Pheochromocytoma. Houston, US.
2022. Clinical trials for metastatic pheochromocytoma and paraganglioma: New horizons, new perspectives. Invited. ISP 2022. Prague, CZ.
2022. HSA-131I-MIBG (AZEDRA®) in Clinical Practice. Invited. ISP 2022. Prague, CZ.
2022. An Open-Label, Phase II Trial of Cabozantinib for Advanced Adrenocortical Carcinoma. Invited. ESMO 2022 Scientific Committee. Paris, FR.
2022. EO2401 (EO) therapeutic vaccine for patients with adrenocortical carcinoma (ACC) and malignant pheochromocytoma/paraganglioma (MPP): phase 1/2 SPENCER study. Invited. ESMO 2022. Paris, FR.
2022. Bone metastases from characterization to therapy : what do we known in 2022 in advanced adrenal tumors. Invited. ENDOCAN. Paris, FR.
2022. A phase 2 open-label study of belzutifan (a HIF-2α inhibitor) monotherapy in patients with advanced/metastatic pheochromocytoma/paraganglioma or pancreatic neuroendocrine tumors. Invited. NANETS - North American Neuroendocrine Tumor Society. Barcelona, ES.
2021. An update of MIBG therapy for patients with metastatic pheochromocytomas and paragangliomas. Invited. XXII Argentina Congress of Nuclear Medicine AABYMN y IX Congreso AACN. Buenos Aires, AR.
2021. Advances in Pheochromocytomas and Paragangliomas. Invited. 19th International Congress of Endocrinology - ICE Virtual 2021. Buenos Aires, AR.
2021. Managing Advanced and Metastatic Pheochromocytoma. Invited. 19th International Congress of Endocrinology - ICE Virtual 2021. Buenos Aires, AR.
2021. Adrenal Nodules Meet the Professor. Invited. 19th International Congress of Endocrinology - ICE 2021. Buenos Aires, AR.
2020. Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond. Invited. 8th Conferences on Endocrinology Hospital Eugenio Espejo. Quito, EC.
2020. Pheochromocytomas and paragangliomas, diagnosis and treatment in the era of personalized medicine. Invited. 8th Conferences on Endocrinology Hospital Eugenio Espejo. Quito, EC.
2020. Pheochromocytoma and Paraganglioma. Invited. PHEiPAS. Madrid, ES.
2020. Acromegalia: La Prueba De Fuego. Invited. XVIII National Congress of Endocrinology. Cuenta, EC.
2020. Pheochromocytoma. Invited. XVIII National Congress of Endocrinology. Cuenta, EC.
2020. Adrenocortical cancer: an overview. Invited. Chilean Congress of Endocrinology. Santiago, CL.
2020. An Update on Multiple Endocrine Neoplasia type 2. Invited. Chilean Congress of Endocrinology. Santiago, CL.
2020. Metastatic Pheochromocytomas and Paragangliomas. Invited. Chilean Congress of Endocrinology. Santiago, CL.
2019. Targeted Radionuclide Therapy for Patients with Metastatic Pheochromocytoma and Paraganglioma. Invited. Seoul National University College of Medicine. Seoul, KR.
2019. Pheochromocytoma and Paraganglioma; Management of Hormonal Syndromes. Invited. 15th Colombian Congress of Endocrinology. Pereira, CO.
2019. Theranostics; Redifferentiation Therapy for Thyroid Cancer, High Specific Activity MIBG for Pheochromocytoma and Paraganglioma, and Other Story. Invited. 15th Colombian Congress of Endocrinology. Pereira, CO.
2019. Malignant Pheochromocytoma and Paraganglioma. Invited. 16th International Workshop on Multiple Endocrine Neoplasia. Houston, US.
2018. Malignant Pheochromocytomas. Invited. VHL Alliance. Houston, US.
2018. Malignant Pheochromocytomas in VHL. Invited. 13th International VHL Medical/Research Symposium. Houston, US.
2018. Management of Cushing's Syndrome - Keynote Speaker. Invited. 3rd Latin American Endocrine Society Congress. Cartagena, CO.
2018. Malignant Pheochromocytoma and Paraganglioma Management; A Perspective from the Hallmarks of Cancer. Invited. 3rd Latin American Endocrine Society Congress. Cartagena, CO.
2017. A Phase 2 Study to Evaluate the Effects of Cabozantinib in Patients with unresectable Metastatic Pheochromocytomas and Paragangliomas. Invited. International Symposium on Phaeochromocytoma. Sydney, AU.
2017. Clinical Trials for Patients with Malignant Pheochromocytomas and Paragangliomas: What Have We Learned? Where Are We Going?. Invited. International Symposium on Phaeochromocytoma. Sydney, AU.
2017. Medullary Thyroid Cancer: To Treat or Not To Treat? And When? Those are the Questions!. Invited. 14th International Congress of the Colombian Association of Endocrinology, Diabetes, and Metabolism. Barranquilla, CO.
2017. Acromegaly: Where Do We Stand? Where Are We Going?. Invited. 14th International Congress of the Colombian Association of Endocrinology, Diabetes, and Metabolism. Barranquilla, CO.
2017. Hypoparathyroidism: New Horizons. Invited. 14th International Congress of the Colombian Association of Endocrinology, Diabetes, and Metabolism. Barranquilla, CO.
2017. Acro-Study. Invited. Somavert Global Advisory Board. Amsterdam, NL.
2016. Topical Issues of Nuclear Medicine: Phaeochromocytoma. Invited. Medical Centre Hospital of President’s Affairs Administration of the Republic of Kazakhstan. Astana, KZ.
2016. Overview Thyroid Cancer. Invited. International Atomic Energy Agency. Houston, US.
2015. Medullary Thyroid Carcinoma: From RET to Tyrosine Kinase Inhibitors. Invited. IAEA-RTC 2015. Limassol, CY.
2015. Multiple Endocrine neoplasia type 2: genotype-Phonotype correlations. Invited. IAEA-RTC 2015. Limassol, CY.
2015. Non-Iodine Avid Thyroid Cancer. Invited. IAEA-RTC 2015. Limassol, CY.
2015. Thyroid cancer: An overview. Invited. IAEA-RTC 2015. Limassol, CY.
2015. Primary Hyperparathyroidism: A Journey Overtime. Invited. IAEA-RTC 2015. Limassol, CY.
2015. Preliminary Dosimetry Results from a Phase II Study Evaluating the Efficacy and Safety of Ultratrace(r) lobenguane l 131 in Patients with Relapsed/Refractory Malignant Pheochromocytoma/Paraganglioma. Invited. Annual Congress of the European Association of Nuclear Medicine. Hamburg, DE.
2015. Progress in Pheochromocytomas. Invited. International Meeting of Egyptian Endocrine Society. Alexandria, EG.
2014. Medullary Thyroid Cancer. Invited. 5th International Ecuadorian Oncology Course. Manta, EC.
2014. Molecular Targeted Therapy for Thyroid Cancer. Invited. 5th International Ecuadorian Oncology Course. Manta, EC.
2014. Molecular Targeted Therapy for Differentiated Thyroid Cancer. Invited. European Thyroid Association. Santiago de Compostela, ES.
2014. New Treatments Against Thyroid Cancer. Invited. European Thyroid Association 38th Annual Meeting. Santiago, ES.
2014. Long-Term Follow-up of a Pivotal Phase II Study of Ultratrace Iobenguane I-131 (AZEDRA) in Patients With Malignant Relapsed/Refractory Pheochromocytoma (pheo)/Paraganglioma (para). Invited. ISP 2014. Kyoto, JP.
2014. Developing Clinical Trials for Patients with Malignant Pheochromocytomas and Paragangliomas in the Times of Personalized Cancer Medicine. Invited. ISP 2014. Kyoto, JP.
2014. Current and Future Recommendations for Patients with Malignant Pheochromocytomas and Sympathetic Paragangliomas. Invited. Institut Gustave Roussey. Paris, FR.
2012. Progress in Pheochromocytoma and Sympathetic Paragangliomas. Invited. 4th International Latin American Endocrine Meeting. Cartagena, CO.
2012. Current Progress on Systemic Therapy Against Metastatic Pheochromocytoma. Invited. International Pheo Symposium. Washington, US.
2012. Targeted Therapies for the Treatment of Pheochromocytoma: Current and Future Approaches to Care. Invited. 10th International VHL Medical Conference. Houston, US.
2011. New Advances in Therapeutic Targets and Clinical Trials. Invited. International Symposium on Pheochromocytoma and Paraganglioma 2011. Paris, FR.
2011. Pheochromocytoma in Children. Invited. XXII Annual Latin American Society of Pediatric Endocrinology. Cartagena, CO.
2011. Papillary Thyroid Carcinoma: Molecular Target Therapy Developments. Invited. Fourth International Congress ISSSTE 2011. Guadalajara, MX.
2010. Pheochromocytomas and Paragangliomas. Invited. Third International Congress ISSSTE 2010. Guadalajara, MX.
2010. Diabetes Mellitus in Cancer Pathology. Invited. Third International Congress ISSSTE 2010. Guadalajara, MX.
2009. Evolving and Future Systemic Treatments Against Malignant Pheochromocytoma and Paraganglioma. Invited. 2009 International Patient Conference on Pheochromocytoma and Paraganglioma. Parsippany, US.
2009. Molecular Targeted Therapy in Thyroid Cancer. Invited. Congress of Colombian Endocrine Society. Bucaramanga, CO.
2009. Molecular Targeted Therapy in Endocrine Neoplasms. Invited. Congress of Colombian Endocrine Society. Bucaramanga, CO.
2009. (1) Long Term Follow-up of Tumor Volumes in Patients with Acromegaly Treated with Pegvisomant in Clinical Trials (2) Bone Mineral Density in Patients with Acromegaly Treated with Pegvisomant. Invited. Pfizer Pharmaceuticals. Ft. Lauderdale, US.
2008. Clinical End Points for Clinical Trials Malignant Pheochromocytomas. Invited. Institut Gustave Roussy. Paris, FR.
2008. End Points for Clinical Trials Against Malignant Pheochromocytomas and Paraganglioma. Invited. Institute Gustave-Roussey. Paris, FR.
2008. Rare Diseases Teach Us How to Treat Islet Cell Malignant Tumors. Invited. Cancer. Cali, CO.
2008. Molecular Target Therapy Against Malignant Pheochromocytomas. Invited. 2nd International Symposium on Pheochromocytoma Queen’s College. Cambridge, GB.
2008. Co-Chair LNET Friday Event/Chairman Saturday Endocrinology Break-out Session. Invited. Latin America Net Meeting - LNETS 2008. Panama City, PA.
2006. Advances in Acromegaly. Invited. Congress of the Mexican Pituitary Society. Mexico City, MX.
2006. Tissue. Invited. The 33rd Annual Meeting of the European Calcified Tissue Society. Prague, CZ.
2006. Endocrinology. Invited. The Best of Endocrinology for Latin America. Cartagena de Indias, CO.
2005. Therapeutic Challenges in Acromegaly. Invited. 45th Congress of the Mexican Endocrine and Nutrition Society. Merida, Yucatan, MX.
2005. TZDs and Insulin Resistance. Invited. Unknown. Bucaramanga and Cucuta, CO.
2005. Teriparatide. Invited. Congress of the Military Forces. Bogotá, CO.
2005. Bone Quality and Bone Turn Over. Invited. The Bone Program of Central America. Panama City, PA.
2005. Cancer Prevention. Invited. International Congress of the Colombian Endocrine Society. Bogotá, CO.
2005. Pituitary. Invited. International Congress of the Colombian Endocrine Society. Bogotá, CO.
2005. Carcinoid Syndrome. Invited. The Central Police Hospital. Bogotá, CO.
2005. Islet Cell Tumors, The Role of the Somatostatin Analogues. Invited. The Oncology Lecture of the Dann Carlton. Bogotá, CO.
2005. Acromegaly: Therapeutic Perspectives. Invited. Colombian Endocrine Society on Pituitary Disorders. Bogotá, CO.
2005. New Advances on Medical Therapy against Osteoporosis. Invited. Colombian Endocrine Society. Bogotá, CO.
2005. Transplant Induced Osteoporosis. Invited. Colombian Endocrine Society. Bogotá, CO.
2005. Bone Physiology. Invited. Colombian Endocrine Society. Bogotá, CO.
2004. Diabetes Mellitus and Cancer: An Encounter of Two Worlds. Invited. National Cancer Institute International Congress. Bogotá, CO.
2004. Endocrine Complications of Non-Hormonal Anti-Neoplastic Therapy. Invited. National Cancer Institute International Congress. Bogotá, CO.
2004. Multiple Endocrine Neoplasia Type 2: An Example of Cancer Prevention. Invited. National Cancer Institute International Congress. Bogotá, CO.
2004. Osteoporosis in Cancer Patients: Another Complication of Cancer. Invited. National Cancer Institute International Congress. Bogotá, CO.
2003. Parathyroid Carcinoma. Invited. First Colombian International Meeting on Head and Neck Diseases. Bogotá, CO.
2003. Medullary Thyroid Carcinoma: Lessons Learned from Genetics. Invited. First Colombian International Meeting on Head and Neck Diseases. Bogotá, CO.
2003. Primary Hyperparathyroidism: Therapeutic Perspectives. Invited. First Colombian International Meeting on Head and Neck Diseases. Bogotá, CO.
2003. Acromegaly and Pituitary Sarcoma: Does Growth Hormone Receptor Antagonism Control Sarcoma Development?. Invited. Salgrenska Hospital. Gothenburg, SE.
2003. Bone Metabolism: Estrogen Replacement Therapy, Bisphosphonates, and Parathyroid Hormone: Therapies against Osteoporosis. Invited. The University of Texas MD Anderson Cancer Center. Madrid, ES.
2002. Humoral Hypercalcemia of Malignancy. Invited. Internal Medicine Grand Rounds. Bogota, CO.
2002. Zoledronic Acid and Other Therapies against Humoral Hypercalcemia of Malignancy. Invited. Gynecology and Obstetrics Grand Rounds. Bogota, CO.
1997. Should Patients with Apparent Sporadic Pheochromocytoma be Evaluated for Hereditary Syndromes?. Invited. Colombian Endocrine Society. Medellin, CO.
1997. Osteoporosis in Breast and Prostate Cancer Survivors. Invited. Colombian Endocrine Society. Medellin, CO.

Formal Peers

2021. Pheochromocytoma /paraganglioma. Houston, Texas, US.
2019. Metastatic Pheochromocytoma and Paraganglioma: Focusing on High Specific Activity MIBG. Houston, Texas, US.
2018. Kidney and Adrenal Cancer Didactic Module. Houston, Texas, US.

Less

Grant & Contract Support

Date:	2018 - 2021
Title:	RFP 2017 Paradifference Grant
Funding Source:	the Paradifference foundation
Role:	Principal Investigator-MDACC

Date:	2010 - 2011
Title:	Pilot Study of Clinical Validity of Veridex Cell Search Assay in Malignant Pheochromocytoma and Paraganglioma
Funding Source:	CCTS Pilot Project RFA from University of Texas Health Science Center
Role:	PI

Selected Publications

Peer-Reviewed Articles

Jimenez C, Andreassen M, Durand A, Moog S, Hendifar A, Welin S, Spada F, Sharma R, Wolin E, Ruether J, Garcia-Carbonero R, Fassnacht M, Capdevila J, Rivero JD, Iliopoulos O, Huillard O, Jang R, Mai K, Artamonova E, Hallqvist A, Else T, Odeleye-Ajakaye A, Gozman A, Naik GS, Berruti A, Investigators L. Belzutifan for Advanced Pheochromocytoma or Paraganglioma. N Engl J Med 393(20):2012-2022, 2025. e-Pub 2025. PMID: 41124218.
Tritos, NA, Carlsson, MO, Vila, G, Jimenez, C, La Torre, D, Wajnrajch, MP, Biller, BM, Cespedes, L, Miller, KK. Disease-specific mortality in patients with acromegaly treated with pegvisomant. Endocrine Connections 14(9), 2025. e-Pub 2025. PMID: 40923548.
Hamidi S, Yedururi S, Hu MI, Busaidy NL, Sherman SI, Jimenez C, Grubbs EG, Maniakas A, Zafereo ME, Subbiah V, Waguespack SG. Efficacy and Safety of Selective RET Inhibitors in Patients with Advanced Hereditary Medullary Thyroid Carcinoma. Thyroid 35(1):6-17, 2024. e-Pub 2024. PMID: 39630530.
Lagana M, Habra MA, Remde H, Almeida MQ, Cosentini D, Pusceddu S, Grana CM, Corssmit EPM, Bongiovanni A, De Filpo G, Lim ES, Zamparini M, Grisanti S, Deutschbein T, Fassnacht M, Fagundes GFC, Pereira MAA, Oldani S, Rota S, Prinzi N, Jimenez C, Berruti A. Adverse skeletal related events in patients with bone-metastatic pheochromocytoma/paraganglioma. Eur J Cancer 208:114122, 2024. e-Pub 2024. PMID: 39047533.
Varghese J, Skefos CM, Jimenez C. Metastatic pheochromocytoma and paraganglioma: Integrating tumor biology in clinical practice. Mol Cell Endocrinol 592:112344, 2024. e-Pub 2024. PMID: 39182716.
Al-Ward R, Brondani VB, Sawani S, Potter CL, Xu G, Waguespack SG, Varghese J, Habra MA, Lu Y, Jimenez C. High-Specific-Activity 131I-MIBG for the Treatment of Advanced Pheochromocytoma and Paraganglioma. Clin Nucl Med 49(7):610-620, 2024. e-Pub 2024. PMID: 38630996.
Campbell MT, Balderrama-Brondani V, Jimenez C, Tamsen G, Marcal LP, Varghese J, Shah AY, Long JP, Zhang M, Ochieng J, Haymaker C, Habra MA. Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial. Lancet Oncol 25(5):649-657, 2024. e-Pub 2024. PMID: 38608694.
Jimenez C, Habra MA, Campbell MT, Tamsen G, Cruz-Goldberg D, Long J, Bassett R, Dantzer R, Balderrama-Brondani V, Varghese J, Lu Y. Cabozantinib in patients with unresectable and progressive metastatic phaeochromocytoma or paraganglioma (the Natalie Trial): a single-arm, phase 2 trial. Lancet Oncol 25(5):658-667, 2024. e-Pub 2024. PMID: 38608693.
Balderrama-Brondani V, Griffin AM, Owen TJ, Merriman KW, Chahla BB, Varghese J, Jimenez C, Waguespack SG, Graham PH, Perrier ND, Fisher SB, Karam JA, Shah AY, Campbell M, Hassan MM, Habra MA. Incidence and geographical distribution of adrenocortical carcinoma: Retrospective analysis of a state cancer registry. Endocr Pract 30(1):25-30, 2024. e-Pub 2023. PMID: 37858722.
Jimenez C, Lu Y. Functional Imaging Evidence of Tumor Response to High-Specific-Activity 131I-MIBG Therapy in an 84-Year-Old Patient With Metastatic Pheochromocytoma/Paraganglioma. Clin Nucl Med 48(5):426-427, 2023. e-Pub 2023. PMID: 36728291.
Jimenez C, Ma J, Roman Gonzalez A, Varghese J, Zhang M, Perrier N, Habra MA, Graham P, Waguespack SG. TNM Staging and Overall Survival in Patients with Pheochromocytoma and Sympathetic Paraganglioma. J Clin Endocrinol Metab 108(5):1132-1142, 2023. e-Pub 2022. PMID: 36433823.
Lu Y, Xu G, Jimenez C. Proposed MIBG Scan-Based Tumor Response Criteria of High-Specific-Activity 131I-MIBG Therapy in Metastatic Pheochromocytoma/Paraganglioma. Clin Nucl Med 48(4):320-323, 2023. e-Pub 2023. PMID: 36758558.
Jimenez C, Chin BB, Noto RB, Dillon JS, Solnes L, Stambler N, DiPippo VA, Pryma DA. Biomarker response to high-specific-activity I-131 MIBG in pheochromocytoma/paraganglioma. Endocr Relat Cancer 30(2), 2023. e-Pub 2022. PMID: 36472300.
Shirali AS, Clemente-Gutierrez U, Huang BL, Lui MS, Chiang YJ, Jimenez C, Fisher SB, Graham PH, Lee JE, Grubbs EG, Perrier ND. Pheochromocytoma recurrence in hereditary disease: does a cortical-sparing technique increase recurrence rate?. Surgery 173(1):26-34, 2023. e-Pub 2022. PMID: 36229248.
Yip L, Duh QY, Wachtel H, Jimenez C, Sturgeon C, Lee C, Velázquez-Fernández D, Berber E, Hammer GD, Bancos I, Lee JA, Marko J, Morris-Wiseman LF, Hughes MS, Livhits MJ, Han MA, Smith PW, Wilhelm S, Asa SL, Fahey TJ, McKenzie TJ, Strong VE, Perrier ND. American Association of Endocrine Surgeons Guidelines for Adrenalectomy: Executive Summary. JAMA Surg 157(10):870-877, 2022. e-Pub 2022. PMID: 35976622.
Wu J, Lakomy DS, Fellman BM, Salcedo MP, Sood AK, Jhingran A, Klopp AH, Iyer RB, Jimenez C, Colbert LE, Eifel PJ, Schmeler KM, Lin LL. Longitudinal Changes in Bone Mineral Measurements Inside and Outside Radiation Fields Used for Cervical Cancer Treatment. Pract Radiat Oncol 12(5):e423-e433, 2022. e-Pub 2022. PMID: 35390531.
Landry JP, Clemente-Gutierrez U, Pieterman CRC, Chiang YJ, Waguespack SG, Jimenez C, Habra MA, Halperin DM, Fisher SB, Graham PH, Perrier ND. Management of adrenocorticotropic hormone-secreting neuroendocrine tumors and the role of bilateral adrenalectomy in ectopic Cushing syndrome. Surgery 172(2):559-566, 2022. e-Pub 2022. PMID: 35437162.
Daher M, Varghese J, Gruschkus SK, Jimenez C, Waguespack SG, Bedrose S, Altameemi L, Bazerbashi H, Naing A, Subaiah V, Campbell MT, Shah AY, Zhang M, Sheth RA, Karam JA, Wood CG, Perrier ND, Graham PH, Lee JE, Habra MA. Temporal Trends in Outcomes in Patients with Adrenocortical Carcinoma: A Multidisciplinary Referral Center Experience. J Clin Endocrinol Metab 107(5):1239-1246, 2022. e-Pub 2022. PMID: 35092681.
Srougi V, Bancos I, Daher M, Lee JE, Graham PH, Karam JA, Henriquez A, Mckenzie TJ, Sada A, Bourdeau I, Poirier J, Vaidya A, Abbondanza T, Kiernan CM, Rao SN, Hamidi O, Sachithanandan N, Hoff AO, Chambo JL, Almeida MQ, Habra MA, MCBV F. Cytoreductive Surgery of the Primary Tumor in Metastatic Adrenocortical Carcinoma: Impact on Patients' Survival. J Clin Endocrinol Metab 107(4):964-971, 2022. e-Pub 2022. PMID: 34850915.
Jimenez C, Xu G, Varghese J, Graham PH, Campbell MT, Lu Y. New Directions in Treatment of Metastatic or Advanced Pheochromocytomas and Sympathetic Paragangliomas: an American, Contemporary, Pragmatic Approach. Current Oncology Reports, 2022. e-Pub 2022.
Liu Z, Ma J, Jimenez C, Zhang M. Pheochromocytoma: A Clinicopathologic and Molecular Study of 390 Cases From a Single Center. Am J Surg Pathol 45(9):1155-1165, 2021. e-Pub 2021. PMID: 34280940.
Lopez-Montoya V, Gutierrez-Restrepo J, Grajales JLT, Aristizabal N, Pantoja D, Roman-Gonzalez A, Jimenez C. Ectopic Cushing syndrome in Colombia. Arch Endocrinol Metab 64(6):687-694, 2021. e-Pub 2021. PMID: 34033277.
Fishbein L, Del Rivero J, Else T, Howe JR, Asa SL, Cohen DL, Dahia PLM, Fraker DL, Goodman KA, Hope TA, Kunz PL, Perez K, Perrier ND, Pryma DA, Ryder M, Sasson AR, Soulen MC, Jimenez C. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma. Pancreas 50(4):469-493, 2021. e-Pub 2021. PMID: 33939658.
Armaiz-Pena G, Flores SK, Cheng ZM, Zhang X, Esquivel E, Poullard N, Vaidyanathan A, Liu Q, Michalek J, Santillan-Gomez AA, Liss M, Ahmadi S, Katselnik D, Maldonado E, Agosto Salgado S, Jimenez C, Fishbein L, Hamidi O, Else T, Lechan R, Tischler A, Benn DE, Dwight T, Clifton-Bligh R, Sanso G, Barontini M, Vincent D, Aronin N, Biondi B, Koops M, Bowhay-Carnes E, Gimenez-Roqueplo AP, Alvarez-Eslava A, Bruder JM, Kitano M, Burnichon N, Ding Y, Dahia PLM. Genotype-phenotype features of germline variants of the TMEM127 pheochromocytoma susceptibility gene: a ten-year update. J Clin Endocrinol Metab 106(1):E350-E364, 2021. e-Pub 2020. PMID: 33051659.
Bancos, I, Atkinson, EJ, Eng, C, Young, WF, Neumann, HP, Yukina, MY, Cohen, D, Waguespack, SG, Pereira, MA, He, X, Bandgar, TR, Donatini, G, Qi, X, Cohn, A, Roslyakova, A, Letizia, C, Fishbein, L, Kaur, RJ, Iniguez-Ariza, N, Murad, MH, Gruber, L, Wachtel, H, Cherenko, S, Jimenez, C, Else, T, Jadhav, S, Fang, Xd, Vaidya, A, Petramala, L, Beltsevich, D, Walz, MK, Corssmit, EP, Wohllk, N, Tufton, N, Links, TP, Ferrara, AM, Tsoy, U, Donegan, D, Peczkowska, M, Timmers, HJ, Morelli, V, Ebbehoj, A, Kirschner, LS, Kunavisarut, T, Larsson, C, Kudlai, I, Hasse-Lazar, K, Barczyński, M, Deutschbein, T, Jonasch, E. Maternal and fetal outcomes in phaeochromocytoma and pregnancy. The Lancet Diabetes and Endocrinology 9(1):13-21, 2021. e-Pub 2021. PMID: 33248478.
Liu Z, Jimenez C, Wood C, Zhang M. A Case of Juxtaglomerular Cell Tumor with an Unusual Clinical Presentation. Human Pathology: Case Reports 22, 2020. e-Pub 2020.
Jimenez C, Subbiah V, Stephen B, Ma J, Milton D, Xu M, Zarifa A, Akhmedzhanov FO, Tsimberidou A, Habra MA, Rodon Anhert J, Fu S, Naing A. Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas. Cancers (Basel) 12(8), 2020. e-Pub 2020. PMID: 32824391.
Lopez-Montoya V, Gutierrez-Restrepo J, Grajales JLT, Aristizabal N, Pantoja D, Roman-Gonzalez A, Jimenez C. Ectopic Cushing syndrome in Colombia. Arch Endocrinol Metab. e-Pub 2020. PMID: 32609152.
Jozaghi Y, Zafereo ME, Perrier ND, Wang JR, Grubbs E, Gross ND, Fisher S, Sturgis EM, Goepfert RP, Lai SY, Best C, Busaidy NL, Cabanillas ME, Dadu R, Gagel RF, Habra MA, Hu MI, Jimenez C, Sherman SI, Thosani S, Varghese J, Waguespack SG, Weitzman S, Ying AK, Graham PH. Endocrine surgery in the Coronavirus disease 2019 pandemic: Surgical Triage Guidelines. Head Neck. e-Pub 2020. PMID: 32437031.
Jimenez C, Núñez R, Wendt R. High-specific-activity iodine 131 metaiodobenzylguanidine for the treatment of metastatic pheochromocytoma or paraganglioma: a novel therapy for an orphan disease. Curr Opin Endocrinol Diabetes Obes. e-Pub 2020. PMID: 32250976.
Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Amir Habra M. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer 8(1), 2020. e-Pub 2020. PMID: 32188704.
Salcedo MP, Sood AK, Jhingran A, Eifel PJ, Klopp AH, Iyer RB, Felllman BM, Jimenez C, Schmeler KM. Pelvic fractures and changes in bone mineral density after radiotherapy for cervical, endometrial, and vaginal cancer: A prospective study of 239 women. Cancer. e-Pub 2020. PMID: 32125711.
Kroiss M, Megerle F, Kurlbaum M, Zimmermann S, Wendler J, Jimenez C, Lapa C, Quinkler M, Scherf-Clavel O, Habra MA, Fassnacht M. Objective response and prolonged disease control of advanced adrenocortical carcinoma with cabozantinib. J Clin Endocrinol Metab. e-Pub 2020. PMID: 31900481.
Tritos NA, Mattsson AF, Vila G, Biller B, Klibanski A, Valluri SR, Hey-Hadavi J, Kelepouris N, Jimenez C. ALL-CAUSE MORTALITY IN PATIENTS WITH ACROMEGALY TREATED WITH PEGVISOMANT AN ACROSTUDY ANALYSIS. Eur J Endocrinol. e-Pub 2020. PMID: 31917681.
Economides MP, Shah AY, Jimenez C, Habra MA, Desai M, Campbell MT. A Durable Response With the Combination of Nivolumab and Cabozantinib in a Patient With Metastatic Paraganglioma: A Case Report and Review of the Current Literature. Front Endocrinol (Lausanne) 11:594264, 2020. e-Pub 2020. PMID: 33329398.
Habra MA, Stephen B, Campbell M, Hess K, Tapia C, Xu M, Rodon Ahnert J, Jimenez C, Lee JE, Perrier ND, Boraddus RR, Pant S, Subbiah V, Hong DS, Zarifa A, Fu S, Karp DD, Meric-Bernstam F, Naing A. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer 7(1):253, 2019. e-Pub 2019. PMID: 31533818.
Cabanillas ME, Ryder M, Jimenez C. Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond. Endocr Rev. e-Pub 2019. PMID: 31322645.
Kutahyalioglu M, Nguyen HT, Kwatampora L, Clarke C, Silva A, Ibrahim E, Waguespack SG, Cabanillas ME, Jimenez C, Hu MI, Sherman SI, Kopetz S, Broaddus R, Dadu R, Wanland K, Williams M, Zafereo M, Perrier N, Busaidy NL. Genetic profiling as a clinical tool in advanced parathyroid carcinoma. J Cancer Res Clin Oncol. e-Pub 2019. PMID: 31309300.
Habra MA, Sukkari MA, Hasan A, Albousen Y, Elsheshtawi MA, Jimenez C, Campbell M, Karam JA, Graham PH, Hatia RI, Phan AT, Varghese J, Hassan MM. Epidemiological Risk Factors for Adrenocortical Carcinoma: A Hospital-based Case-Control Study. Int J Cancer. e-Pub 2019. PMID: 31241762.
Pryma DA, Chin BB, Noto RB, Dillon JS, Perkins S, Solnes L, Kostakoglu L, Serafini AN, Pampaloni MH, Jensen J, Armor T, Lin T, White T, Stambler N, Apfel S, DiPippo V, Mahmood S, Wong V, Jimenez C. Efficacy and Safety of High-Specific-Activity I-131 MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma. J Nucl Med. e-Pub 2018. PMID: 30291194.
Roman-Gonzalez A, Zhou S, Ayala-Ramirez M, Shen C, Waguespack SG, Habra MA, Karam JA, Perrier N, Wood CG, Jimenez C. Impact of Surgical Resection of the Primary Tumor on Overall Survival in Patients With Metastatic Pheochromocytoma or Sympathetic Paraganglioma. Ann Surg 268(1):172-178, 2018. e-Pub 2018. PMID: 28257320.
Sagiv O, Kandl TJ, Thakar SD, Thuro BA, Busaidy NL, Cabanillas M, Jimenez C, Dadu R, Graham PH, Debnam JM, Esmaeli B. Extraocular Muscle Enlargement and Thyroid Eye Disease-like Orbital Inflammation Associated with Immune Checkpoint Inhibitor Therapy in Cancer Patients. Ophthalmic Plast Reconstr Surg. e-Pub 2018. PMID: 29927883.
Romero Arenas MA, Rich TA, Hyde SM, Busaidy NL, Cote GJ, Hu MI, Gagel RF, Gidley PW, Jimenez C, Kupferman ME, Peterson SK, Sherman SI, Ying A, Bassett RL, Waguespack SG, Perrier ND, Grubbs EG. Recontacting Patients With Updated Genetic Testing Recommendations for Medullary Thyroid Carcinoma and Pheochromocytoma or Paraganglioma. Ann Surg Oncol 25(5):1395-1402, 2018. e-Pub 2018. PMID: 29427212.
Jimenez C, Ayala-Ramirez M, Liu J, Nunez R, Gagel RF. Inhibition of Growth Hormone Receptor Activation by Pegvisomant may Increase Bone Density in Acromegaly. Horm Metab Res 43(1):55-61, 2018. e-Pub 2018. PMID: 21104581.
Noreña JA, Niño CD, Gallego S, Builes-Barrera CA, Castro DC, Román-González A, Jimenez C. Calcitriol-mediated hypercalcemia secondary to granulomatous disease caused by soft-tissue filler injection: a case report. Clin Cases Miner Bone Metab 14(3):340-346, 2017. e-Pub 2017. PMID: 29354165.
Jasim S, Suman VJ, Jimenez C, Harris P, Sideras K, Burton JK, Worden FP, Auchus RJ, Bible KC. Phase II trial of Pazopanib in Advanced/Progressive Malignant Pheochromocytoma and Paraganglioma. Endocrine 57(2):220-225, 2017. e-Pub 2017. PMID: 28685225.
Roman-Gonzalez A, Jimenez C. Malignant Pheochromocytoma-Paraganglioma: Pathogenesis, TNM Staging, and Current Clinical Trials. Curr Opin Endocrinol Diabetes Obes 24(3):174-183, 2017. e-Pub 2017. PMID: 28234804.
Tritos NA, Chanson P, Jimenez C, King D, Jönsson PJ, Klibanski A, Biller BM. Effectiveness of First-Line Pegvisomant Monotherapy in Acromegaly: An ACROSTUDY Analysis. Eur J Endocrinol 176(2):213-220, 2017. e-Pub 2017. PMID: 27932529.
Xu JY, Grubbs EG, Waguespack SG, Jimenez C, Gagel RF, Sosa JA, Sellin RV, Dadu R, Hu MI, Trotter CS, Jackson M, Rich TA, Hyde SM, Sherman SI, Cote GJ. Medullary Thyroid Carcinoma Associated with Germline RET K666N Mutation. Thyroid 26(12):1744-1751, 2016. e-Pub 2016. PMID: 27673361.
Xu JY, Murphy WA, Milton DR, Jimenez C, Rao SN, Habra MA, Waguespack SG, Dadu R, Gagel RF, Ying AK, Cabanillas ME, Weitzman SP, Busaidy NL, Sellin RV, Grubbs E, Sherman SI, Hu MI. Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma. J Clin Endocrinol Metab 101(12):4871-4877, 2016. e-Pub 2016. PMID: 27662441.
Xu JY, Handy B, Michaelis CL, Waguespack SG, Hu MI, Busaidy N, Jimenez C, Cabanillas ME, Fritsche HA, Cote GJ, Sherman SI. Detection and Prognostic Significance of Circulating Tumor Cells in Patients with Metastatic Thyroid Cancer. J Clin Endocrinol Metab:jc20162567. e-Pub 2016. PMID: 27575943.
Waingankar N, Bratslavsky G, Jimenez C, Russo P, Kutikov A. Pheochromocytoma in Urologic Practice. Eur Urol Focus 1(3):231-240, 2016. e-Pub 2016. PMID: 28078330.
Phan LM, Fuentes-Mattei E, Wu W, Velazquez-Torres G, Sircar K, Wood CG, Hai T, Jimenez C, Cote GJ, Ozsari L, Hofmann MC, Zheng S, Verhaak R, Pagliaro L, Cortez MA, Lee MH, Yeung SC, Habra MA. Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma. Cancer Res 75(19):4131-42, 2015. e-Pub 2015. PMID: 26282167.
Rich T, Jackson M, Roman-Gonzalez A, Shah K, Cote GJ, Jimenez C. Metastatic Sympathetic Paraganglioma in a Patient With Loss of the SDHC Gene. Fam Cancer. e-Pub 2015. PMID: 26162468.
Ozsari L, Kutahyalioglu M, Elsayes KM, Vicens RA, Sircar K, Jazaerly T, Waguespack SG, Busaidy NL, Cabanillas ME, Dadu R, Hu MI, Vassilopoulou-Sellin R, Jimenez C, Lee JE, Habra MA. Preexisting Adrenal Masses in Patients With Adrenocortical Carcinoma: Clinical and Radiological Factors Contributing to Delayed Diagnosis. Endocrine. e-Pub 2015. PMID: 26206754.
Thosani S, Ayala-Ramirez M, Roman-Gonzalez A, Zhou S, Thosani N, Bisanz A, Jimenez C. Constipation: An Overlooked, Unmanaged Symptom of Patients with Pheochromocytoma and Sympathetic Paraganglioma. Eur J Endocrinol. e-Pub 2015. PMID: 26060051.
Martucci VL, Emaminia A, Del Rivero J, Lechan RM, Magoon BT, Galia A, Fojo T, Leung S, Lorusso R, Jimenez C, Shulkin BL, Audibert JL, Adams KT, Rosing DR, Vaidya A, Dluhy RG, Horvath KA, Pacak K. Succinate Dehydrogenase Gene Mutations in Cardiac Paragangliomas. Am J Cardiol 115(12):1753-9, 2015. e-Pub 2015. PMID: 25896150.
Jimenez C, Waguespack SG. Functional Imaging for Pheochromocytoma-Paraganglioma: A Step Closer to Understanding Its Place in Clinical Practice. Endocrine. e-Pub 2015. PMID: 26113425.
Dadu R, Shah K, Busaidy NL, Waguespack SG, Habra MA, Ying AK, Hu MI, Bassett R, Jimenez C, Sherman SI, Cabanillas ME. Efficacy and Tolerability of Vemurafenib in Patients with BRAFV600E - Positive Papillary Thyroid Cancer: MD Anderson Cancer Center Off Label Experience. J Clin Endocrinol Metab 100(1):E77-81, 2015. e-Pub 2015. PMID: 25353071.
Baudin E, Habra MA, Deschamps F, Cote G, Dumont F, Cabanillas M, Arfi-Roufe J, Berdelou A, Moon B, Al Ghuzlan A, Patel S, Leboulleux S, Jimenez C. Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma. Eur J Endocrinol 171(3):R111-22, 2014. e-Pub 2014. PMID: 24891137.
Rich TA, Feng L, Busaidy N, Cote GJ, Gagel RF, Hu M, Jimenez C, Lee JE, Perrier N, Sherman SI, Waguespack SG, Ying A, Grubbs E. Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutations. Thyroid 24(7):1096-106, 2014. e-Pub 2014. PMID: 24617864.
Dadu R, Devine C, Hernandez M, Waguespack SG, Busaidy NL, Hu MI, Jimenez C, Habra MA, Sellin RV, Ying AK, Cote GJ, Sherman SI, Cabanillas ME. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab 99(6):2086-94, 2014. e-Pub 2014. PMID: 24628550.
Hu MI, Ying AK, Jimenez C. Update on medullary thyroid cancer. Endocrinol Metab Clin North Am 43(2):423-42, 2014. e-Pub 2014. PMID: 24891170.
Dadu R, Waguespack SG, Sherman SI, Hu MI, Busaidy NL, Jimenez C, Habra MA, Ying AK, Bassett RL, Cabanillas ME. Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer. Oncologist 19(5):477-82, 2014. e-Pub 2014. PMID: 24733667.
Shawa H, Elsayes KM, Javadi S, Morani A, Williams MD, Lee JE, Waguespack SG, Busaidy NL, Vassilopoulou-Sellin R, Jimenez C, Habra MA. Adrenal Ganglioneuroma: Features and Outcomes of 27 Cases at a Referral Cancer Centre. Clin Endocrinol (Oxf) 80(3):342-7, 2014. e-Pub 2014. PMID: 24033606.
Shawa H, Elsayes KM, Javadi S, Sircar K, Jimenez C, Habra MA. Clinical and Radiological Features of Pheochromocytoma/Ganglioneuroma Composite Tumors: A Case Series with Comparative Analysis. Endocr Pract:1-19. e-Pub 2014. PMID: 24641930.
Abadin SS, Ayala-Ramirez M, Jimenez C, Dickson PV, Liang Y, Lazar AJ, Hornick JL, Cotton M, Sui D, Rich T, Lee JE, Grubbs E, Perrier ND. Impact of Surgical Resection for Subdiaphragmatic Paragangliomas. World J Surg 38(3):733-41, 2014. e-Pub 2014. PMID: 24390286.
Cabanillas ME, Hu MI, Jimenez C, Grubbs EG, Cote GJ. Treating Medullary Thyroid Cancer in the Age of Targeted Therapy. Int J Endocr Oncol 1(2):203-216, 2014. e-Pub 2014. PMID: 25908961.
Cabanillas ME, Hu MI, Jimenez C. Medullary Thyroid Cancer in the Era of Tyrosine Kinase Inhibitors: To Treat or Not to Treat-And with Which Drug-Those Are the Questions. J Clin Endocrinol Metab, 2014. e-Pub 2014. PMID: 25238206.
Santarpia L, Calin GA, Adam L, Ye L, Fusco A, Giunti S, Thaller C, Paladini L, Zhang X, Jimenez C, Trimarchi F, El-Naggar AK, Gagel RF. A miRNA signature associated with human metastatic medullary thyroid carcinoma. Endocr Relat Cancer 20(6):809-23, 2013. e-Pub 2013. PMID: 24127332.
Morris LF, Harris RS, Milton DR, Waguespack SG, Habra MA, Jimenez C, Vassilopoulou-Sellin R, Lee JE, Perrier ND, Grubbs EG. Impact and Timing of Bilateral Adrenalectomy for Refractory Adrenocorticotropic Hormone-Dependent Cushing s Syndrome. Surgery 154(6):1174-83; discussion 1183-4, 2013. e-Pub 2013. PMID: 24383115.
Ayala-Ramirez M, Jasim S, Feng L, Ejaz S, Deniz F, Busaidy N, Waguespack SG, Naing A, Sircar K, Wood CG, Pagliaro L, Jimenez C, Vassilopoulou-Sellin R, Habra MA. Adrenocortical carcinoma: Clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol 169(6):891-9, 2013. e-Pub 2013. PMID: 24086089.
Thosani S, Ayala-Ramirez M, Palmer L, Hu MI, Rich T, Gagel RF, Cote G, Waguespack SG, Habra MA, Jimenez C. The Characterization of Pheochromocytoma and Its Impact on Overall Survival in Multiple Endocrine Neoplasia Type 2. J Clin Endocrinol Metab 98(11):e1813-9, 2013. e-Pub 2013. PMID: 24030942.
Sridhara SK, Yener M, Hanna EY, Rich T, Jimenez C, Kupferman ME. Genetic Testing in Head and Neck Paraganglioma: Who, What, and Why?. J Neurol Surg B Skull Base 74(4):236-40, 2013. e-Pub 2013. PMID: 24436918.
Jimenez C, Rohren E, Habra MA, Rich T, Jimenez P, Ayala-Ramirez M, Baudin E. Current and Future Treatments for Malignant Pheochromocytoma and Sympathetic Paraganglioma. Curr Oncol Rep 15(4):356-71, 2013. e-Pub 2013. PMID: 23674235.
Thosani N, Thosani SN, Kumar S, Nugent Z, Jimenez C, Singh H, Guha S. Reduced Risk of Colorectal Cancer with Use of Oral Bisphosphonates: A Systematic Review and Meta-analysis. J Clin Oncol 31(5):623-30, 2013. e-Pub 2013. PMID: 23269990.
Ayala-Ramirez M, Palmer JL, Hoffman MC, de la Cruz M, Moon BS, Waguespack SG, Habra MA, Jimenez C. Bone Metastases and Skeletal-Related Events in Patients with Malignant Pheochromocytoma and Sympathetic Paraganglioma. J Clin Endocrinol Metab. e-Pub 2013. PMID: 23436918.
Grubbs EG, Rich TA, Ng C, Bhosale PR, Jimenez C, Evans DB, Lee JE, Perrier ND. Long-term outcomes of surgical treatment for hereditary pheochromocytoma. J Am Coll Surg 216(2):280-9, 2013. e-Pub 2013. PMID: 23317575.
Habra MA, Ejaz S, Feng L, Das P, Deniz F, Grubbs EG, Phan A, Waguespack SG, Ayala-Ramirez M, Jimenez C, Perrier ND, Lee JE, Vassilopoulou-Sellin R. A Retrospective Cohort Analysis of the Efficacy of Adjuvant Radiotherapy after Primary Surgical Resection in Patients with Adrenocortical Carcinoma. J Clin Endocrinol Metab 98(1):192-7, 2013. e-Pub 2013. PMID: 23150683.
Dickson PV, Alex GC, Grubbs EG, Jimenez C, Lee JE, Perrier ND. Robotic-Assisted Retroperitoneoscopic Adrenalectomy: Making a Good Procedure Even Better. Am Surg 79(1):84-9, 2013. e-Pub 2013. PMID: 23317617.
Carhill AA, Cabanillas ME, Jimenez C, Waguespack SG, Habra MA, Hu M, Ying A, Vassilopoulou-Sellin R, Gagel RF, Sherman SI, Busaidy NL. The Non Investigational Use of Tyrosine Kinase Inhibitors in Thyroid Cancer: Establishing a Standard for Patient Safety and Monitoring. J Clin Endocrinol Metab 98(1):31-42, 2013. e-Pub 2013. PMID: 23185034.
Shawa H, Deniz F, Bazerbashi H, Hernandez M, Vassilopoulou-Sellin R, Jimenez C, Habra MA. Mitotane-Induced Hyperlipidemia: A Retrospective Cohort Study. Int J Endocrinol 2013:624962, 2013. e-Pub 2013. PMID: 24348556.
Ayala-Ramirez M, Chougnet CN, Habra MA, Palmer JL, Leboulleux S, Cabanillas ME, Caramella C, Anderson P, Al Ghuzlan A, Waguespack SG, Deandreis D, Baudin E, Jimenez C. Treatment with Sunitinib for Patients with Progressive Metastatic Pheochromocytomas and Sympathetic Paragangliomas. J Clin Endocrinol Metab 97(11):4040-50, 2012. e-Pub 2012. PMID: 22965939.
Chuang HH, Deniz F, Sircar K, Jimenez C, Rubin De Celis C, Wood CG, Habra MA. [18F]Fluorodeoxyglucose Positron Emission Tomography-Guided Therapy in Metastatic Adrenocortical Carcinoma: An Illustrative Case. J Clin Oncol 30(26):e246-9, 2012. e-Pub 2012. PMID: 22649135.
Morris GS, Landry CL, Grubbs EG, Jimenez C, Busaidy NL, Perrier ND. Older Patients with Primary Hyperparathyroidism have Greater than Age Predicted Functional Deficits. Endocrine Practice:1-23. e-Pub 2012. PMID: 22784831.
Ayala-Ramirez M, Feng L, Habra MA, Rich T, Dickson PV, Perrier N, Phan A, Waguespack S, Patel S, Jimenez C. Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: Insights from the largest single-institutional experience. Cancer 118(11):2804-12, 2012. e-Pub 2012. PMID: 22006217.
Rianon N, Alex G, Callender G, Jimenez C, Hu M, Grubbs E, Moreno M, Wathoo C, Petak S, Perrier N. Preoperative Serum Osteocalcin May Predict Postoperative Elevated Parathyroid Hormone in Patients with Primary Hyperparathyroidism. World J Surg 36(6):1320-6, 2012. e-Pub 2012. PMID: 22278606.
Plouin PF, Fitzgerald P, Rich T, Ayala-Ramirez M, Perrier ND, Baudin E, Jimenez C. Metastatic Pheochromocytoma and Paraganglioma: Focus on Therapeutics. Horm Metab Res. e-Pub 2012. PMID: 22314389.
Peck BW, Rich TA, Jimenez C, Kupferman ME. A Novel SDHB Mutation Associated with Hereditary Head and Neck Paraganglioma. Laryngoscope 121(12):2572-5, 2011. e-Pub 2011. PMID: 22109755.
Dickson PV, Alex GC, Grubbs EG, Ayala-Ramirez M, Jimenez C, Evans DB, Lee JE, Perrier ND. Posterior Retroperitoneoscopic Adrenalectomy is a Safe and Effective Alternative to Transabdominal Laparoscopic Adrenalectomy for Pheochromocytoma. Surgery 150(3):452-8, 2011. e-Pub 2011. PMID: 21878230.
Thosani S, Jimenez C. Opioid Induced Biochemical Alterations of the Neuroendocrine Axis. Expert Rev Endocrinol Metab 6(5):705-713, 2011. e-Pub 2011. PMID: 30780884.
Waguespack SG, Rich TA, Perrier ND, Jimenez C, Cote GJ, Medscape. Management of medullary thyroid carcinoma and MEN2 syndromes in childhood. Nat Rev Endocrinol. e-Pub 2011. PMID: 21862994.
Varghese J, Ayala-Ramirez M, Rich T, Rohren E, Rao P, Jimenez C. Novel Germline SDHD Mutation: Diagnosis and Implications to the Patient. Fam Cancer 10(2):365-71, 2011. e-Pub 2011. PMID: 21318381.
Khan MI, Waguespack SG, Habra MA, Broaddus R, Jimenez C. Acute-Onset Ectopic Adrenocorticotropic Hormone Syndrome Secondary to Metastatic Endometrioid Carcinoma of the Ovaries as a Fatal Complication. J Clin Oncol 29(16):e462-4, 2011. e-Pub 2011. PMID: 21422435.
Dickson PV, Jimenez C, Chisholm GB, Kennamer DL, Ng C, Grubbs EG, Evans DB, Lee JE, Perrier ND. Posterior Retroperitoneoscopic Adrenalectomy: A Contemporary American Experience. J Am Coll Surg 212(4):659-65, 2011. e-Pub 2011. PMID: 21463807.
Varghese J, Rich T, Jimenez C. Benign Familial Hypocalciuric Hypercalcemia. Endocr Pract 17 Suppl 1:13-7, 2011. e-Pub 2011. PMID: 21478088.
Khan MI, Habra MA, McCutcheon IE, Nogueras-González GM, Devin JK, Busaidy NL, Levine NB, Lindstrom W, Kagan D, Jimenez C, Waguespack SG. Random Postoperative Day 3 Cortisol as a Predictor of Hypothalamic-Pituitary-aAdrenal Axis Integrity After Transsphenoidal Surgery. Endocr Pract:1-25. e-Pub 2011. PMID: 21454228.
Ayala-Ramirez M, Feng L, Johnson MM, Ejaz S, Habra MA, Rich T, Busaidy N, Cote GJ, Perrier N, Phan A, Patel S, Waguespack S, Jimenez C. Clinical Risk Factors for Malignancy and Overall Survival in Patients with Pheochromocytomas and Sympathetic Paragangliomas: Primary Tumor Size and Primary Tumor Location as Prognostic Indicators. J Clin Endocrinol Metab 96(3):717-25, 2011. e-Pub 2011. PMID: 21190975.
Ejaz S, Vassilopoulou-Sellin R, Busaidy NL, Hu MI, Waguespack SG, Jimenez C, Ying AK, Cabanillas M, Abbara M, Habra MA. Cushing Syndrome Secondary to Ectopic Adrenocorticotropic Hormone Secretion: The University of Texas MD Anderson Cancer Center Experience. Cancer. e-Pub 2011. PMID: 21412758.
Jasim S, Ying AK, Waguespack SG, Rich TA, Grubbs EG, Jimenez C, Hu MI, Cote G, Habra MA. Multiple Endocrine Neoplasia Type 2B with a RET Proto-Oncogene A883F Mutation Displays a More Indolent Form of Medullary Thyroid Carcinoma Compared with a RET M918T Mutation. Thyroid 21(2):189-92, 2011. e-Pub 2011. PMID: 21186952.
Gómez K, Varghese J, Jiménez C. Medullary Thyroid Carcinoma: Molecular Signaling Pathways and Emerging Therapies. J Thyroid Res 2011:815826, 2011. e-Pub 2011. PMID: 21687607.
Ayala-Ramirez M, Habra MA, Busaidy N, Cote G, Rich T, Waguespack S, Jimenez C. A Catecholamine Crisis on Mount Kilimanjaro: A Hypoxia Effect?. J Travel Med 17(6):424-6, 2010. e-Pub 2010. PMID: 21050326.
Moskovic DJ, Smolarz JR, Stanley D, Jimenez C, Williams MD, Hanna EY, Kupferman ME. Malignant Head and Neck Paragangliomas: Is There an Optimal Treatment Strategy?. Head Neck Oncol 2(1):23. e-Pub 2010. PMID: 20863367.
Waguespack SG, Rich T, Grubbs E, Ying AK, Perrier ND, Ayala-Ramirez M, Jimenez C. A Current Review of the Etiology, Diagnosis, and Treatment of Pediatric Pheochromocytoma and Paraganglioma. J Clin Endocrinol Metab 95(5):2023-37, 2010. e-Pub 2010. PMID: 20215394.
Morris GS, Grubbs EG, Hearon CM, Gantela S, Lee JE, Evans DB, Holmes HM, Busaidy NL, Jimenez C, Perrier ND. Parathyroidectomy Improves Functional Capacity in "Asymptomatic" Older Patients with Primary Hyperparathyroidism: A Randomized Control Trial. Ann Surg 251(5):832-7, 2010. e-Pub 2010. PMID: 20395857.
Ayala-Ramirez M, Callender GG, Kupferman ME, Rich TA, Chuang HH, Trent J, Perrier ND, Goodarzi M, Jimenez C. Paraganglioma Syndrome Type 1 in a Patient with Carney-Stratakis Syndrome. Nat Rev Endocrinol 6(2):110-5, 2010. e-Pub 2010. PMID: 20098451.
Habra MA, Núñez R, Chuang H, Ayala-Ramirez M, Rich T, Kyle K, Jimenez C. Fatal Hypoglycemia in Malignant Pheochromocytoma: Direct Glucose Consumption as Suggested By (18)F-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography Imaging. Endocrine 37(1):209-12, 2010. e-Pub 2010. PMID: 20963572.
Lodish MB, Adams KT, Huynh TT, Prodanov T, Ling A, Chen C, Shusterman S, Jimenez C, Merino M, Hughes M, Cradic KW, Milosevic D, Singh RJ, Stratakis CA, Pacak K. Succinate Dehydrogenase Gene Mutations Are Strongly Associated with Paraganglioma of the Organ of Zuckerkandl. Endocrine Related Cancer 17(3):581-8, 2010. e-Pub 2010. PMID: 20418362.
Perrier ND, Balachandran D, Wefel JS, Jimenez C, Busaidy N, Morris GS, Dong W, Jackson E, Weaver S, Gantela S, Evans DB, Grubbs EG, Lee JE. Prospective, Randomized, Controlled Trial of Parathyroidectomy Versus Observation in Patients With "Asymptomatic" Primary Hyperparathyroidism. Surgery 146(6):1116-22, 2009. e-Pub 2009. PMID: 19879613.
Weaver S, Doherty DB, Jimenez C, Perrier ND. Peer-Reviewed, Evidence-Based Analysis of Vitamin D and Primary Hyperparathyroidism. World J Surg 144(6):852-8, 2009. e-Pub 2009. PMID: 19308641.
Shin SH, Holmes H, Bao R, Jimenez C, Kee SS, Potylchansky E, Lee JE, Evans DB, Perrier ND. Outpatient Minimally Invasive Parathyroidectomy is Safe for Elderly Patients. J Am Coll Surg 208(6):1071-6, 2009. e-Pub 2009. PMID: 19476894.
Stava CJ, Jimenez C, Hu MI, Vassilopoulou-Sellin R. Skeletal Sequelae of Cancer and Cancer Treatment. J Cancer Surviv 3(2):75-88. e-Pub 2009. PMID: 19412668.
Perrier ND, Edeiken B, Nunez R, Gayed I, Jimenez C, Busaidy N, Potylchansky E, Kee S, Vu T. A Novel Nomenclature to Classify Parathyroid Adenomas. World J Surg 33(3):412-6, 2009. e-Pub 2009. PMID: 19148701.
Jimenez C, Cabanillas ME, Santarpia L, Jonasch E, Kyle KL, Lano EA, Matin SF, Nunez RF, Perrier ND, Phan A, Rich TA, Shah B, Williams MD, Waguespack SG. Use of the Tyrosine Kinase Inhibitor Sunitinib in a Patient with von Hippel-Lindau Disease: Targeting Angiogenic Factors in Pheochromocytoma and other von Hippel-Lindau Disease-related Tumors. J Clin Endocrinol Metab 94(2):386-91, 2009. e-Pub 2009. PMID: 19017755.
Jaishuen A, Jimenez C, Sirisabya N, Li Y, Zheng H, Hu W, Urbauer DL, Kavanagh JJ. Poor Survival Outcome With Moderate and Severe Hypercalcemia in Gynecologic Malignancy Patients. Int J Gynecological Cancer 19(2):178-85, 2009. e-Pub 2009. PMID: 19395991.
Habra MA, Jimenez C, Huang SC, Cote GJ, Murphy WA, Gagel RF, Hoff AO. Expression Analysis of Fibroblast Growth Factor-23, Matrix Extracellular Phospho Glycoprotein, Secreted Frizzled-Related Protein-4, and Fibroblast Growth Factor-7: Identification of Fibroblast growth factor-23 and Matrix Extracellular Phospho Glycoprotein as Major Factors Involved in Tumor-Induced Osteomalacia. Endocrine Practice 14(9):1108-14, 2008. e-Pub 2008. PMID: 19158050.
Grubbs EG, Rafeeq S, Jimenez C, Feng L, Lee JE, Evans DB, Perrier ND. Preoperative Vitamin D Replacement Therapy in Primary Hyperparathyroidism: Safe and Beneficial?. Surgery 144(6):852-8; discussion 858-9, 2008. e-Pub 2008. PMID: 19040987.
Jimenez C, Burman P, Abs R, Clemmons DR, Drake WM, Hutson KR, Messig M, Thorner MO, Trainer PJ, Gagel RF. Follow-up of Pituitary Tumor Volume in Patients With Acromegaly Treated with Pegvisomant in Clinical Trials. Eur J Endocrinol 159(5):517-23, 2008. e-Pub 2008. PMID: 18708436.
Perrier ND, Kennamer DL, Bao R, Jimenez C, Grubbs EG, Lee JE, Evans DB. Posterior Retroperitoneoscopic Adrenalectomy: Preferred Technique for Removal of Benign Tumors and Isolated Metastases. Ann Surg 248(4):666-74, 2008. e-Pub 2008. PMID: 18936580.
Rich TA, Jonasch E, Matin S, Waguespack SG, Gombos DS, Santarpia L, Stolle C, Jimenez C. A Novel Von Hippel-Lindau Point Mutation Presents As Apparently Sporadic Pheochromocytoma. Cancer Invest 26(6):642-6, 2008. e-Pub 2008. PMID: 18584357.
Stava CJ, Jimenez C, Vassilopoulou-Sellin R. Endocrine Sequelae of Cancer and Cancer Treatments. J Cancer Surviv 1(4):261-74. e-Pub 2007. PMID: 18648961.
Jiménez C, Cote G, Arnold A, Gagel RF. Review: Should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes?. J Clin Endocrinol Metab 91(8):2851-8, 2006. e-Pub 2006. PMID: 16735498.
Jimenez C, Yang Y, Kim HW, Al-Sagier F, Berry DA, El-Naggar AK, Patel S, Vassilopoulou-Sellin R, Gagel RF. Primary Hyperparathyroidism and Osteosarcoma: Examination of a Large Cohort Identifies Three Cases of Fibroblastic Osteosarcoma. J Bone Miner Res 20(9):1562-8, 2005. e-Pub 2005. PMID: 16059628.
Levis S, Gomez A, Jimenez C, Veras L, Ma F, Lai S, Hollis B, Roos BA. Vitamin d deficiency and seasonal variation in an adult South Florida population. J Clin Endocrinol Metab 90(3):1557-62, 2005. e-Pub 2005. PMID: 15634725.
Jimenez C, Moran SA, Sereti I, Wynne S, Yen PM, Falloon J, Davey RT, Sarlis NJ. Graves Disease After Interleukin-2 Therapy in a Patient With Human Immunodeficiency Virus Infection. Thyroid 14(12):1097-102, 2004. e-Pub 2004. PMID: 15650365.
Busaidy NL, Jimenez C Habra MA, Schultz PN, El-Naggar AK, Clayman GL, Asper JA, Diaz EM, Evans DB, Gagel RF, Garden A, Hoff AO, Lee JE, Morrison WH, Rosenthal DI, Sherman SI, Sturgis EM, Waguespack SG, Weber RS, Wirfel K, Vassilopoulou-Sellin R. Parathyroid Carcinoma: A 22-year Experience. Head and Neck 26(8):716-26, 2004. e-Pub 2004. PMID: 15287039.
Jimenez C, Habra MA, Huang SC, El-Naggar A, Shapiro SE, Evans DB, Cote G, Gagel RF. Pheochromocytoma and Medullary Thyroid Carcinoma: A New Genotype-Phenotype Correlation of the RET Protooncogene 891 Germline Mutation. J Clin Endocrinol Metab 89(8):4142-5, 2004. e-Pub 2004. PMID: 15292360.
Jimenez C, Dang GT, Schultz PN, El-Naggar A, Shapiro S, Barnes EA, Evans DB, Vassilopoulou-Sellin R, Gagel RF, Cote GJ, Hoff AO. A Novel Point Mutation of the RET Proto-Oncogene Involving the Second Intracellular Tyrosine Kinase Domain in a Family with Medullary Thyroid Carcinoma. J Clin Endocrinol Metab 7(7):3521-26, 2004. e-Pub 2004. PMID: 15240641.

Invited Articles

Jimenez C. SDHB-Associated Pheochromocytomas: What is Their Clinical Behavior?. Ann Surg Oncol 31(13):9007-9013, 2024. e-Pub 2024. PMID: 39382746.
Casey RT, Hendriks E, Deal C, Waguespack SG, Wiegering V, Redlich A, Akker S, Prasad R, Fassnacht M, Clifton-Bligh R, Amar L, Bornstein S, Canu L, Charmandari E, Chrisoulidou A, Freixes MC, de Krijger R, de Sanctis L, Fojo A, Ghia AJ, Huebner A, Kosmoliaptsis V, Kuehlen M, Raffaelli M, Lussey-Lepoutre C, Marks SD, Nilubol N, Parasiliti-Caprino M, Timmers HHJLM, Zietlow AL, Robledo M, Gimenez-Roqueplo AP, Grossman AB, Taieb D, Maher ER, Lenders JWM, Eisenhofer G, Jimenez C, Pacak K, Pamporaki C. International consensus statement on the diagnosis and management of phaeochromocytoma and paraganglioma in children and adolescents. Nat Rev Endocrinol 20(12):729-748, 2024. e-Pub 2024. PMID: 39147856.
Laganà M, Habra MA, Remde H, Almeida MQ, Cosentini D, Pusceddu S, Grana CM, Alberto Bongiovanni EPC, Filpo GD, Lim ES, Zamparini M, Grisanti S, Deutschbein T, Fassnacht M, Fagundes GF, A Pereira MA, Oldani S, Rota S, Prinzi N, Jimenez C, Berruti A. Adverse Skeletal Related Events in Patients with Bone-Metastatic Pheochromocytoma/Paraganglioma, 2024. e-Pub 2024.

Review Articles

Fischer A, Del Rivero J, Wang K, Nolting S, Jimenez C. Systemic therapy for patients with metastatic pheochromocytoma and paraganglioma. Best Pract Res Clin Endocrinol Metab 39(1):101977, 2025. e-Pub 2025. PMID: 39880697.
Jimenez C, Sukrithan, Perez, Pandit-Taskar. Management of metastatic pheochromocytomas and paragangliomas: when and what. Curr Probl Cancer 51, 2024. e-Pub 2024. PMID: 39024846.
Jimenez, C, Baudrand, R, Uslar, T, Bulzico, DA. Perspective review. Therapeutic Advances in Medical Oncology 16, 2024. e-Pub 2024. PMID: 39574494.
Jimenez C, Baudrand R, Uslar T, Bulzico D. Perspective review: lessons from successful clinical trials and real-world studies of systemic therapy for metastatic pheochromocytomas and paragangliomas. Ther Adv Med Oncol 16:17588359241301359, 2024. e-Pub 2024. PMID: 39574494.
Toledo RA, Jimenez C, Armaiz-Pena G, Arenillas C, Capdevila J, Dahia PLM. Hypoxia Inducible factor 2 alpha (HIF2α) inhibitors: targeting genetically driven tumor hypoxia. Endocr Rev 44(2):312-322, 2023. e-Pub 2022. PMID: 36301191.
Jimenez, C, Xu, G, Varghese, J, Graham, PH, Campbell, M, Lu, Y. New Directions in Treatment of Metastatic or Advanced Pheochromocytomas and Sympathetic Paragangliomas. Current oncology reports 24(1):89-98, 2022. e-Pub 2022. PMID: 35061191.
Jimenez C, Armaiz-Pena G, Dahia PLM, Lu Y, Toledo RA, Varghese J, Habra MA. Endocrine and Neuroendocrine Tumors Special Issue-Checkpoint Inhibitors for Adrenocortical Carcinoma and Metastatic Pheochromocytoma and Paraganglioma: Do They Work?. Cancers (Basel) 14(3), 2022. e-Pub 2022. PMID: 35158739.
Amar L, Pacak K, Steichen O, Akker SA, Aylwin SJB, Baudin E, Buffet A, Burnichon N, Clifton-Bligh RJ, Dahia PLM, Fassnacht M, Grossman AB, Herman P, Hicks RJ, Januszewicz A, Jimenez C, Kunst HPM, Lewis D, Mannelli M, Naruse M, Robledo M, Taïeb D, Taylor DR, HJLM T, Treglia G, Tufton N, Young WF, Lenders JWM, Gimenez-Roqueplo AP, Lussey-Lepoutre C. International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. Nat Rev Endocrinol 17(7):435-444, 2021. e-Pub 2021. PMID: 34021277.
Dahia PLM, Clifton-Bligh R, Gimenez-Roqueplo AP, Robledo M, Jimenez C. Metastatic pheochromocytoma and paraganglioma: proceedings of the MEN2019 workshop. Endocr Relat Cancer 27(8):T41-T52, 2020. e-Pub 2020. PMID: 32069214.
Jimenez C, Fazeli S, Román-Gonzalez A. Antiangiogenic therapies for pheochromocytoma and paraganglioma. Endocr Relat Cancer 27(7):R239-R254, 2020. e-Pub 2020. PMID: 32369773.
Jasim S, Jimenez C. Metastatic pheochromocytoma and paraganglioma: Management of endocrine manifestations, surgery and ablative procedures, and systemic therapies. Best Pract Res Clin Endocrinol Metab:101354. e-Pub 2019. PMID: 31685417.
Jimenez C, Erwin W, Chasen B. Targeted Radionuclide Therapy for Patients with Metastatic Pheochromocytoma and Paraganglioma: From Low-Specific-Activity to High-Specific-Activity Iodine-131 Metaiodobenzylguanidine. Cancers (Basel) 11(7), 2019. e-Pub 2019. PMID: 31330766.
Toledo R, Jimenez C. Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitors. F1000Res 7, 2018. e-Pub 2018. PMID: 30109021.
Jimenez C. Treatment for Patients With Malignant Pheochromocytomas and Paragangliomas: A Perspective From the Hallmarks of Cancer. Front Endocrinol (Lausanne) 9:277, 2018. e-Pub 2018. PMID: 29892268.
Jimenez P, Tatsui C, Jessop A, Thosani S, Jimenez C. Treatment for Malignant Pheochromocytomas and Paragangliomas: 5 Years of Progress. Curr Oncol Rep 19(12):83, 2017. e-Pub 2017. PMID: 29081018.
Gao J, He Q, Subudhi S, Aparicio A, Zurita-Saavedra A, Lee DH, Jimenez C, Suarez-Almazor M, Sharma P. Review of Immune-Related Adverse Events in Prostate Cancer Patients Treated with Ipilimumab: MD Anderson Experience. Oncogene 34(43):5411-7, 2015. e-Pub 2015. PMID: 25659583.
Santarpia L, Habra MA, Jiménez C. Malignant Pheochromocytomas and Paragangliomas: Molecular Signaling Pathways and Emerging Therapies. Horm Metab Res 41(9):680-6, 2009. e-Pub 2009. PMID: 19343618.
Jiménez C, Hu MI, Gagel RF. Management of Medullary Thyroid Carcinoma. Endocrinol Metab Clin North Am 37(2):481-96, 2008. e-Pub 2008. PMID: 18502338.
Hu MI, Gagel RF, Jimenez C. Bone Loss in Patients With Breast or Prostate Cancer. Curr Osteoporos Rep 5(4):170-8, 2007. e-Pub 2007. PMID: 18430392.
Jimenez C, Gagel RF. Genetic Testing in Endocrinology: Lessons Learned from Experience With Multiple Endocrine Neoplasia Type 2 (MEN2). Growth Hormone IGF Res 14 Suppl A:S150-7, 2004. e-Pub 2004. PMID: 15135800.

Abstracts

Laganà M, Balderrama-Brondani V, Herrera KR, Chahla B, Yaylaci F, Bassett RL, Jimenez C, Varghese J, Waguespack SG, Campbell MT, Shah AY, Rojas Hernandez CM, Habra MA. Venous thromboembolism in adrenocortical carcinoma: a retrospective analysis. Oncologist 29(7):575-580, 2024. e-Pub 2024. PMID: 38776552.
Jimenez C, MD. EO2401, a new peptide immunotherapy against cancer, in combination with nivolumab, induces a strong and durable immune response in patients from the EOADR1-19/SPENCER Study, 2023. e-Pub 2023.
Walter T, Gong K, Nakamura E, Iliopoulos O, Jimenez C, Capdevila J, Liu P, Jin F, Naik GS, Jonasch E. LITESPARK-015 Cohort B1: A Phase 2 Open-Label Study of Belzutifan (An HIF-2α Inhibitor) Monotherapy in Patients With von Hippel-Lindau (VHL) Disease–Associated Tumors, 2023. e-Pub 2023.
Jimenez C. Quality of Life Assessments for Advanced Pheochromocytoma and Paraganglioma Patients that Received High-Specific-Activity I-131 MIBG: Results from a Pivotal Phase 2 Clinical Trial, 2022. e-Pub 2022.
Jimenez C. Multidisciplinary Perspectives on High-Specific-Activity I-131 MIBG in Advanced Pheochromocytoma and Paraganglioma (PPGL), 2022. e-Pub 2022.
Jimenez C. A Phase 2 Open-Label Study of Belzutifan (a HIF-2Î± Inhibitor) Monotherapy in Patients with Advanced/Metastatic Pheochromocytoma/Paraganglioma or Pancreatic Neuroendocrine Tumors, 2022. e-Pub 2022.
Jimenez C. Sympathetic Paraganglioma Associated with X-Linked Hypophosphatemia: Is There a Genetic Link?. AACE Annual Meeting 2022, 2022. e-Pub 2022.
Jimenez C, Chin BB, Noto RB, Dillon JS, Solnes L, DiPippo V, Stambler N, Wong V, Pryma DA. Biochemical Tumor Marker Status and Its Role in Treatment Response in Patients Who Received High-Specific-Activity I-131 MIBG in Advanced Pheochromocytoma and Paraganglioma (PPGL): Results from a Pivotal Phase 2 Clinical Trial. ENDO 2021, 2021. e-Pub 2021.
Wu J, Lakomy DS, Fellman BM, Salcedo MP, Sood, AK, Jhingran A, Klopp AH, Iyer RB, Jimenez C, Colbert LE, Schmeler KM, Eifel PJ, Lin LL. Bone mineral density of in-field and out-of-field lumbar vertebrae in cervical cancer patients. ASTRO, 2021. e-Pub 2021.
Jimenez C, Chin BB, Noto RB, Dillon JS, Solnes L, DiPippo V, Stambler N, Wong V, Pryma DA. Updated Long-term Survival and Safety from a Multi-Center, Open-Label, Pivotal Phase 2 Study of AZEDRA&[reg] in Patients with Unresectable, Locally Advanced or Metastatic Pheochromocytoma or Paraganglioma. The Journal of Urology, 2020. e-Pub 2020.
Jimenez C, Chin BB, Noto RB, Dillon JS, Solnes LB, DiPippo VA, Stambler N, Wong V, Pryma DA. A Multi-Center, Open-Label, Pivotal Phase 2 Study of Azedra® (HSA I-131-MIBG) in Patients with Unresectable, Locally Advanced or Metastatic Pheochromocytoma or Paraganglioma: Updated Long-Term Survival and Safety. ENDO 2020, 2020. e-Pub 2020.
Jimenez C, Chin BB, Noto RB, Dillon JS, Solnes LB, DiPippo VA, Stambler N, Wong V, Pryma DA. A Multi-Center, Open-Label, Pivotal Phase 2 Study of Azedra® (HSA I-131-MIBG) in Patients with Unresectable, Locally Advanced or Metastatic Pheochromocytoma or Paraganglioma: Updated Long-Term Survival and Safety, 2020. e-Pub 2020.
Herrera RA, Jimenez C. Bilateral Pheochromocytoma as Incidental Finding in a Patient with Neurofibromatosis Type 1. ENDO 2020, 2020. e-Pub 2020.
Faazeli S, Dadu R, Waguespack SG, Sherman SI, Busaidy L, Hu MI, Jimenez C, Habra MA, Williams M, Altameemi L, Poropatich K, Routbort MJ, Luthra R, Patel KP, Cabanillas M. TRK-Fusion Thyroid Cancer: A Clinical Overview in a Large Population at a Single Cancer Center. ENDO 2020, 2020. e-Pub 2020.
Bedrose SSD, Altameemi L, Daher M, Tamsen de Rosa G, Varghese JM, Jimenez C, Campbell M, Habra MA. Trial in Progress Interim Report: A Phase II Clinical Trial Using Single Agent Cabozantinib in Advanced Adrenocortical Carcinoma. ENDO 2020, 2020. e-Pub 2020.
Campbell M, XieW, Shah A, Habra MA, Jimenez C, Venkatesan A, Killbridge K, Bubley G, Mortazavi A, Bilen M, McKay R, Choueiri T, McGregor B. Initial Results of a Phase II study of Nivolumab and Ipilimumab in Metastatic Adrenal Tumors. Annals of Oncology, 2019. e-Pub 2019.
Thosani S, Best C, Lavis V, Habra MA, Busaidy N, Varghese J, Hu M, Cabanillas M, Dadu R, Gagel R, Waguespack S, Weitzman SP, Jimenez C. Improving Documentation for Hypoglycemia Treatment in Hospitalized Patients at MD Anderson Cancer Center. 2019 Internal Medicine Research Retreat University of Texas MD Anderson Cancer Center, 2019. e-Pub 2019.
Tritos NA, Mattsson AF, Vila G, Biller BMK, Klibanski A, Valluri A, Hey-Hadavi J, Kelepouris N, Jimenez C. Mortality among patients with acromegaly on pegvisomant therapy: An ACROSTUDY analysis. Pituitary Society, 2019. e-Pub 2019.
Pryma D, Bennett C, Noto R, Dillon J, Perkins S, Solnes O, Lale K, Serafin A, Pampaloni M, Matthay K, Jimenez C. Special Interest Session: High Impact Clinical Trials. RSNA 2018. e-Pub 2018.
Jimenez C. Azddra (iobenguane i 131) in patients with malignant, recurrent and/or unresectable pheochromocytoma or paraganglioma (PPGL): Updated efficacy and safety results from a multi-center, open-label, pivotal phase 2 study. ASCO 2018 - Chicago, Il. e-Pub 2018.
Salcedo MP, Sood, AK, Jhingran A, Eifel P, Klopp A, Felllman BM, Jimenez C, Schmeler KM. 17th Biennial Meeting of the International Gynecologic Cancer Society. IGCS -2018 - Kyoto, Japan. e-Pub 2018.
Jimenez C, Pandit K. Staging Of Patients With Malignant Pheochromocytoma and Paraganglioma. AACE 2018 - Boston, MA. e-Pub 2018.
Kutahyalioglu M, Ibrahim EY, Williams MD, Dadu R, Habra MA, Hu M, Jimenez C, Waguespack S, Ying AK, Graham PH, Busaidy NL. Malignant Struma Ovarii: A Case Series. AACE 2017, Austin TX, 2017. e-Pub 2017.
Roman-Gonzalez A, Sierra J, Marquez J, Donado J, Jimenez C. Pheochromocytoma and Paraganglioma in Colombia. Insights to a Rare Disease in Developing Countries and Opportunities to Improve Gaps in the Care of Pheo/PG Patients. ENDO 2017, Orlando, Fl, 2017. e-Pub 2017.
Roman-Gonzalez A, Marquez J, Pablo Duenas J, Varela G, Jimenez C. Composite Pheochromocytoma/Paraganglioma: Case Report and Analysis of the Literature. ENDO 2017, Orlando, Fl, 2017. e-Pub 2017.
Kutahyalioglu M, Jimenez C, Williams JKY. An adolescent with granulomatous mycosis fungoides complicated with calcitriol mediated hypercalcemia. ASBMR 2016, Atlanta, GA, 2016. e-Pub 2016.
Kwatampora L, Hamidi V, Lewis C, Williams J, Williams M, Hu M, William M, Perrier ND, Jimenez C, Busaidy N. Parathyroid Carcinoma associated with Multiple Brown Tumors Mimicking Fibrous Histiocytoma—a Unique Case of Two Rare Conditions. AACE 2016, Orlando, Florida, 2016. e-Pub 2016.
Gagel RF, Jimenez C, Waguespack SG. Severe Hypocalcemia Associated with Osteoblastic Prostate Cancer Metastases in a Patient with Prolonged Bisphosphonate Use: Clinical Considerations. ENDO 2016, Boston, MA, 2016. e-Pub 2016.
Jimenez C. Medullary Thyroid Cancer with Bone Metastases and the Effect of Antiresorptive Agents on Skeletal Related Events (Oral Presentation). ENDO 2016, Boston, MA, 2016. e-Pub 2016.
Jimenez C. Effectiveness of First-Line Pegvisomant Monotherapy in Acromegaly â€“ an Acrostudy Analysis (Oral Presentation). ENDO 2016, Boston, MA, 2016. e-Pub 2016.
Roman-Gonzalez A, Builes-Barrera CA, Velez-Hoyos A, Jimenez C. Thyroid Paraganglioma. 15th International Thyroid Congress, 2015. e-Pub 2015.
Roman-Gonzalez A, Ayala-Ramirez M, Christakis I, Qiu W, Waguespack S, Habra M, Perrier N, Jimenez C. Surgical Resection of the Primary Tumor in Patients with Metastatic Pheochromocytoma and Sympathetic Paraganglioma: Impact on Survival. North America Neuroendocrine Tumor Society, NANETS, Austin, October 15-17, 2015, 2015. e-Pub 2015.
Jimenez C, Pryma DA, Sullivan DC, Schwarz JK, Noto RB, Stambler N, Armor T, Jensen JD, Israel RJ. Long Term Follow-up of a Pivotal Phase 2 Study of Ultratrace Iobenguane I-131 (AZEDRA) in Patients with Malignant Relapsed/Refractory Pheochromocytoma (Pheo)/Paraganglioma (Para). ENDO 2015, San Diego, CA, 2015. e-Pub 2015.
Phan L, Fuentes-Mattel E, Velazquez-torres G, Sircar K, Jimenez C, Cote GJ, Hofmann MC, Lee MH, Yeung SCJ, Habra MA. Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma: A Potential Therapeutic Target. ENDO 2015, San Diego, CA, 2015. e-Pub 2015.
Weitzman SP, Peicher KT, Dadu R, Hu MI, Jimenez C, Gardner C, Qayyum A, Hernandez M, Cabanillas ME. Salvage Therapy: When a Tyrosine Kinase Inhibitor (TKI) Fails in Advanced Medullary Thyroid Cancer (MTC). ENDO 2015, San Diego, CA, 2015. e-Pub 2015.
Busaidy NL, Cabanillas ME, Dadu R, Jimenez C, Habra MA, Vaporciyan A, Morris L, Perrier ND, Hoff AO. Metastatic Parathyroid Carcinoma and Hypercalcemia Responds to Treatment with Sorafenib. Endo 2014, Chicago, IL, 2014. e-Pub 2014.
Pryma DA, Sullivan DC, Jimenez C. Long-Term Follow-up of a Pivotal Phase II Study of Ultratrace Iobenguane I-131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma (pheo)/Paraganglioma (para). J Compr Canc Netw, 2014. e-Pub 2014.
Shawa H, Elsayes KM, Javadi S, Morani A, Williams MD, Waguespack SG, Busaidy NL, Vassilopoulou-Sellin R, Jimenez C, Habra MA. Adrenal Ganglioneuroma: 20-year experience in a tertiary referral cancer center. ENDO 2013, San Francisco, CA, 2013. e-Pub 2013.
Del Rivero J, Emaminia A, Del Mundo Galia A, Leung S, Lorusso R, Jimenez C, Shulkin BL, Audibert JL, Adams KT, Rosing D, Fojo A, Vaidya A, Loughran EG, Dluhy RG, Horvath K, Pacak K. Cardiac Paragangliomas are Commonly Associated with Succinate Dehydrogenase Gene Mutations. ENDO 2013, San Francisco, CA, 2013. e-Pub 2013.
Deniz F, Bazerbashi H, Jimenez C, Vassilopoulou-Sellin R, Habra MA. Mitotane induced HDL-cholesterol elevation: A retrospective cohort study. ENDO 2013, San Francisco, CA, 2013. e-Pub 2013.
Pryma DA, Coleman RE, Noto R, Perini RF, Jimenez C, Pampaloni M, Serafini A, Wahl R, Kostakoglu L, Grigsy PW, Schwarz J, Ford K, Conley J, LaFrance N, BarrettJ, Babich J. Interim Results of an Open-label, Single-Arm Trial of Ultratrace I-101-Iobenguane in Patients with Metastatic Pheochromocytoma/Paraganglioma (Pheo). 5th Annual NANETS Conference, San Diego, CA; October 11-13, 2012, 2012. e-Pub 2012.
Patel P, Busaidy N, Jimenez C. Graves Opthalmopathy and Pretibial Myxedema with Primary Hypothyroidism. ENDO 2012, Houston, TX, 2012. e-Pub 2012.
Williams M, Mills G, Grubbs E, Kupferman M, Habra M, Jimenez C, Hale K, Cabanillas M, Megahed N, Busaidy N. Molecular Profiling of Advanced Thyroid Carcinomas. ENDO 2012, Houston, TX, 2012. e-Pub 2012.
Pryma DA, Coleman RE, Noto R, Goldsmith SJ, Perini RF, Jimenez C, Pampaloni MH, Serafini AN, Wahl RL, Kostakoglu L, Conley J, Ford K, LaFrance D, Babich JW. Interim Results of an Open-Label, Single-Arm Trial of Ultratrace I-131-Iobenguane in Patients with Metastatic Pheochromocytoma/Paraganglioma (Pheo). 2012 ASCO Annual Meeting, Chicago, IL, 2012. e-Pub 2012.
Ying A, Jimenez C, Waguespack S, Rich T, Ayala-Ramirez M, Perrier N, Hu M, Habra M, Grubbs E, Cote G, Cabanillas M, Busaidy N, Thosani S. Characterization of Pheochromocytomas in MEN 2 with RET codon 918 and 634 mutations. ENDO 2012, Houston, TX, 2012. e-Pub 2012.
Habra M, Ejaz S, Feng L, Das P, Deniz F, Grubbs EG, Phan AT, Waguespack S, Ayala-Ramirez M, Jimenez C, Vassilopoulou-Sellin R. Adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma: Retrospective cohort analysis. 2012 ASCO Annual Meeting, Chicago, IL, 2012. e-Pub 2012.
Habra MA, DeCelis C, Wood C, Jimenez C, Sircar K, Chuang H, Deniz F. Fluorodeoxyglucose Positron Emission Tomography-Guided Therapy in Metastatic Adrenocortical Carcinoma: An Illustrative Case. ENDO 2012, Houston, TX, 2012. e-Pub 2012.
Thosani S, Jimenez C, Guha S. Use of Oral Bisphosphonates and Risk of Colorectal Cancer: A Systemic Review and Meta-analysis. Digestive Disease Week 2012 - American Society of Gastroenterology, 2011. e-Pub 2011.
Cabanillas ME, Cash KP, Mattiuzzi GN, Kantarjian HM, O'Brien S, Hu M, Jimenez C, Gagel RF. A Randomized, Double Blinded Study of Risedronate Versus Placebo for the Prevention of Bone Loss in Patients Receiving High Dose Corticosteroids for the Treatment of Acute Lymphocytic Leukemia and Lymphoblastic Lymphoma, 2011. e-Pub 2011.
Dickson PV, Alex GC, Grubbs EG, Jimenez C, Lee JE, Perrier ND. Robotic Retroperitoneoscopic Adrenalectomy: Making a Good Procedure Even Better. ACS 97th Annual Clinical Congress, San Francisco, CA, 2011. e-Pub 2011.
Thosani S, Waguespack S, Lavis V, Jimenez C. Interleukin-2 Therapy and the Extremes of Autoimmune Thyroid Disease. ATA 81st Annual Meeting, Indian Wells, CA, 2011. e-Pub 2011.
Thosani S, Edeiken-Monroe B, Gong Y, Jimenez C. Leukemic Infiltration of the Thyroid Gland. ATA 81st Annual Meeting, Indian Wells, CA, 2011. e-Pub 2011.
Alex G, Rianon N, Callender G, Moreno M, Jimenez C, Hu M, Grubbs E, Lee J, Perrier N. Preoperative Serum Osteocalcin May Predict Postoperative Elevated Parathyroid Hormone in Patients with Primary Hyperparathyroidism. International Association of Endocrine Surgeons (IAES), Yokohama, Japan, 2011. e-Pub 2011.
Vu T, Warneke C, Grubbs L, Jimenez C, Perrier N. Vitamin D Supplementation Does Not Alter Size or Perfusion of Parathyroid Adenomas. International Association of Endocrine Surgery (IAES), Yokohama, Japan, 2011. e-Pub 2011.
Pryma DA, Barrett JA, Coleman RE, Noto R, Jimenez C, Pampaloni MH, Serafini AN, Wahl RL, Kostakoglu L, LaFrance ND, Babich JW. Preliminary Data from an Ongoing Phase 2b Study of No Carrier Added 131 I-iobenguane (nca-MIBG) in Patients with Maligant Pheochromocytoma (Pheo). 2011 ASCO Annual Meeting, Chicago, IL, 2011. e-Pub 2011.
Varghese J, Ayala-Ramirez M, Vaporciyan A, Liao Z, Habra M, Jimenez C. Mediastinal Paragnaglioma: The University of Texas MD Anderson Cancer Center (MDACC) Experience. ENDO 2011, Boston, MA, 2011. e-Pub 2011.
Ayala-Ramirez M, Habra M, Rich T, Cote G, Busaidy N, Anderson P, Waguespack S, Phan A, Patel S, Jimenez C. Experience with the Tyrosine Kinase Inhibitor Sunitinib in Metastatic Pheochromocytomas and Paragangliomas. ENDO 2011, Boston, MA, 2011. e-Pub 2011.
Ayala-Ramirez M, Habra M, Busaidy N, Perrier N, Rich T, Waguespack S, Phan A, Patel S, Jimenez C. Clinical Benefits of Chemotherapy in Patients with Metastatic Pheochromocytomas and Sympathetic Paragangliomas: Review of the Largest Single-Institution Experience. ENDO 2011, Boston, MA, 2011. e-Pub 2011.
Alford EM, Murphy WA, Shah J, Jimenez C, Lee B, Hu M. An Unusual Case of Acquired and Rapid Osteosclerosis. ENDO 2011, Boston, MA, 2011. e-Pub 2011.
Dickson PV, Jimenez C, Chisholm GB, Kennamer DL, Ng C, Grubbs EG, Evans DB, Lee JE, Perrier ND. Posterior Retroperitoneoscopic Adrenalectomy: A Contemporary American Experience (Shiply Award Winner). Southern Surgical Association, 2010. e-Pub 2010.
Schmeler KM, Jhingran A, Iyer RB, Munsell M, Kim E, Jimenez C, Sun CC, Moore CL, Kitaka S, Eifel PJ, Klopp AH, Sood AK. Significant Decreases in Bone Mineral Density Associated with Pelvic Radiotherapy: A Prospective Logitudinal Study of Women with Gynecologic Malignancies. 13th Biennial Meeting of the International Gynecological Cancer Society (IGCS 2010), Prague, 2010. e-Pub 2010.
Ying AK, Jasim S, Waguespack SG, Rich TA, Grubbs EG, Jimenez C, Cote G, Habra MA. Multiple Endocrine Neoplasia Type 2b with A ret Proto-Oncogene A883F Mutation Displays a More Indolent form of Medullary Thyroid Carcinoma Compared with RET M918T Mutation. MEN 2010 12th International Workshop on Multiple Endocrine Neoplasia, Gubbio, Italy, 2010. e-Pub 2010.
Barrera T, Rich TA, Perrier ND, McCutcheon IE, Jimenez C, Habra MA. Pheochromocytoma and Cushing's Disease: A Rare Combination with Unclear Etiology. The Endocrine Society's 92nd Annual Meeting and Expo, San Diego, CA, 2010. e-Pub 2010.
Khan MI, McCutcheon IE, Nogueras-Gonzalez GM, Devin JK, Jimenez C, Habra MA, Levine NB, Waguespack SG. Post-Operative Day 3 Cortisol as a Predictor of HPA Axis Integrity after Transsphenoidal Surgery. The Endocrine Society's 92nd Annual Meeting and Expo, San Diego, CA, 2010. e-Pub 2010.
Ayala-Ramirez M, Hernandez M, Habra MA, Busaidy NL, Cote G, Rich TA, Waguespack SG, Jimenez C. Survival Rates in Patients with Metastatic Pheochromocytomas and Paragangliomas. The Endocrine Society's 92nd Annual Meeting and Expo, San Diego, CA, 2010. e-Pub 2010.
Busaidy NL, Vu T, Grubbs E, Urbauer D, Kim E, Landry C, Jimenez C, Hu MI, Waguespack SG, Gomez H, Perrier ND. 4D Neck CT Versus SPECT/CT Using Tc99m Sestamibi in the Localization of Parathyroid Adenomas: Which Study and When?. The Endocrine Society's 92nd Annual Meeting and Expo, San Diego, CA, 2010. e-Pub 2010.
Michaelis CL, Cote GJ, Santarpia L, Klein MJ, Gornet TG, Fritsche HA, Busaidy NL, Waguespack SG, Cabanillas ME, Hu MI, Jimenez C, Sherman SI. Detection of Circulating Tumor Cells (CTCs) in Patients with Thyroid Cancer. The Endocrine Society's 92nd Annual Meeting and Expo, San Diego, CA, 2010. e-Pub 2010.
Ayala-Ramirez M, Habra MA, Busaidy NL, Cote G, Rich TA, Waguespack SG, Jimenez C. A Catecholamine Crisis on Mount Kilimanjaro: A Hypoxia Effect?. The Endocrine Society's 92nd Annual Meeting and Expo, San Diego, CA, 2010. e-Pub 2010.
Ejaz S, Waguespack SG, Sellin RV, Busaidy NL, Jimenez C, Ying AK, Hu MI, Cabanillas ME, Gagel RF, Habra MA. ACTH-Dependent Ectopic Cushing's Syndrome: The University of Texas M.D. Anderson Cancer Center Experience. The Endocrine Society's 92nd Annual Meeting and Expo, San Diego, CA, 2010. e-Pub 2010.
Westin JR, Thompson MA, Cataldo VD, Toth BB, Sanjorjo P, Bourgeois S, Jimenez C, Murphy W, Fanale M, Fayad L, Fowler N, Kwak L, McLaughlin P, Neelapu S, Pro B, Rodriguez A, Shah J, Hagemeister FB. Bone Loss in Lymphoma Patients Prior to Receiving Front-Line Therapy. Clinical Lymphoma, Myeloma & Leukemia 20(3 / June 2010):E32, 2010. e-Pub 2010.
Westin JR, Thompson MA, Cataldo VD, Toth BB, Sanjorjo P, Bourgeois S, Jimenez C, Murphy WA, Kwak LW, Hagemeister FB. The Effect of Zoledronic Acid on the Prevention of Bone Loss in Lymphoma Patients Receiving First-line Therapy, 2010. e-Pub 2010.
Lodish MB, Adams K, Huynh TT, Prodanov T, Ling A, Jimenez C, Stratakis CA, Pacak K. Succinate Dehydrogenase Mutations Are Strongly Associated With Paraganglioma of the Organ of Zuckerkandl in Pediatric and Adult Patients. 8th European Society of Pediatric Endocrinology, 2009. e-Pub 2009.
Cataldo VD, Thompson MA, Toth BB, Sanjorjo P, Bourgeois S, Bekele BN, Jimenez C, Murphy WA, Huen AO, Byfield SA, Hagemeister FB. Zoledronic Acid for the Prevention of Bone Loss in Patients with Previously Untreated Lymphoma Undergoing Chemotherapy. ASCO, Orlando, 2009, 2009. e-Pub 2009.
Guthikonda A, Jimenez C. Thyroid Leukemia. AACE, Houston, 2009, 2009. e-Pub 2009.
Callender GG, Moreno M, Jimenez C, Hu MI, Grubbs EG. Osteocalcin: Preoperative Predictor of Bone Hunger after Parathyroidectomy. AACE, Houston 2009, 2009. e-Pub 2009.
Cabanillas M, Nunez R, Williams M, Jimenez C. Suture Granulomas Represent a False Positive MIBG Result, 2nd International Symposium on Pheochromocytoma. Queens College Cambridge, UK, Sept 2008, 2008. e-Pub 2008.
Jimenez C, Clemmons DR, Drake WM, Hutson KR, Thorner MO, Trainer PJ, Gagel RF. Long-Term Follow-up of Pituitary Tumor Volume in Patients with Acromegaly treated with Pegvisomant. ENDO 2005, 2005. e-Pub 2005.
Jimenez C, Habra A, Busaidy N, Vasudevan A, Gagel RF, Sarlis, NJ. Capecitabine and Radiotherapy Induce Disease Stabilization in a Case of Poorly Differentiated Follicular Thyroid Carcinoma, 2004. e-Pub 2004.
Busaidy NL, Hymes SR, Jimenez C, Habra MA, Sarlis NJ. Progression of Medullary Thyroid Carcinoma Manifested as Skin Metastasis with Inflammatory Features, 2004. e-Pub 2004.
Jimenez C, Habra MA, Huang SC, El-Naggar A, Shapiro SE, Evans DB, Cote G, Gagel RF. Pheochromocytoma and Medullary Thyroid Carcinoma: A New Genotype-Phenotype Correlation of the RET Proto-Oncogene 891 Germline Mutation. J Clin Endocrinol Metab 89(8):4142-5, 2004. e-Pub 2004. PMID: 15292360.
Jimenez C, Habra MA, Busaidy N, Vasudevan A, Gagel RF, Sarlis NJ. Portal Hypertension: Another Complication of Metastatic Medullary Thyroid Carcinoma, 2004. e-Pub 2004.
Busaidy N, Habra MA, Jimenez C, Gagel RF. Diabetes Mellitus: A Possible Paraneoplastic Syndrome?, 2004. e-Pub 2004.
Asper JA, Rosenthal DI, Garden AS, Clayman G, Jimenez C, Ang KK. Parathyroid Carcinoma: The Role of Postoperative Radiation Therapy (Oral Presentation), 2004. e-Pub 2004.
Busaidy N, Jimenez C, Habra MA, Gagel RF. Secondary or Tertiary Hyperparathyroidism in Tumor Induced Osteomalacia, 2004. e-Pub 2004.
Habra MA, Jimenez C, Busaidy N, Vassilopoulou-Sellin R. Hyperprolactinemia as Initial Manifestation of Cowden Syndrome, 2004. e-Pub 2004.
Jimenez C, Burman P, Clemmons D, Drake W, Thorner M, Trainer P, Gagel RF. Long-term follow-up of Pituitary Tumor Volume in Patients with Acromegaly Treated with Pegvisomant, 2004. e-Pub 2004.
Garavito G, Neira F, Mejia C, Restrepo L, Penagos P, Yeung, SCJ, Jimenez C. A Woman with Acromegaly, a Normal Pituitary, and a Parasellar Mass. Where is the Excessive Growth Hormone Secretion Coming From?, 2003. e-Pub 2003.
Jimenez C, Kim HW, Al-Sagier F, El-Naggar A, Sellin R, Berry D, Gagel RF. Primary Hyperparathyroidism and Osteosarcoma: Examination of a Large Cohort Identifies Unique Characteristics (Oral Presentation). 25th Annual Meeting of the American Society for Bone and Mineral Research, 2003. e-Pub 2003.
Jimenez C, Maple S, Schultz P, Gagel R. Treatment of Acromegaly with Pegvisomant, a Growth Hormone Receptor Antagonist, Does Not Reduce Bone Mass, 2003. e-Pub 2003.
Jimenez C, Maple S, Al-Sghir F, Gagel R. Lack of Further Growth in the Size of 2 Pituitary Growth Hormone Producing Tumors After Initiation of Pegvisomant Therapy, 2003. e-Pub 2003.
Jimenez C, Maple S, Gagel R. Bone Mineral Density in Patients with Acromegaly under Therapy with Pegvisomant. ENDO, Philadelphia 2002, 2003. e-Pub 2003.
Busaidy N, Jimenez C, Habra M, Schultz P, El-Naggar A, Clayman G, Vassilopoulou-Sellin R. Parathyroid Carcinoma, The University of Texas M. D. Anderson Cancer Center Experience, 2003. e-Pub 2003.
Jimenez C, Habra M, Busaidy N, Wirfel K, El-Naggar A, Vassilopoulou-Sellin R. Parathyroid Carcinoma, MD Anderson Cancer Center Experience. Head and Neck Surgery Journal, 2003. e-Pub 2003.
Roman F, Bentancourt M, Case C, Jimenez C, Wirfel K. Non-Islet Cell Tumor Hypoglycemia: Case presentation, Hormonal Evaluation and Options for Palliative Treatment, 2002. e-Pub 2002.
Levis S, Gomez A, Jimenez C, Vera L, Hollis BW, Lai S, Roos B. Decreased Seasonal Variation in Vitamin D Levels in Medical Outpatients in Miami, Florida (Unites States). ENDO Denver, CO, 2003, 2001. e-Pub 2001.
Gomez A, Veras L, Jimenez C, Hollis BW, Lai S, Roos B, Lewis S. Diminished Seasonal Vitamin D and PTH Changes in South Florida. Geriatrics, Chicago, IL,, 2001. e-Pub 2001.
Levis S, Gomez A, Jimenez C, Veras L, Hollis BW, Lai S, Roos B. Sustained 25(OH) Vitamin D Levels Throughout the Year in the Elderly Population of South Florida. ECTS, Madrid, Spain May 2001, 2000. e-Pub 2000.
Jimenez C, Campbell M, Shah AY, Graham PH, Varghese J, Moussa M, Habra M. Circulating Tumor DNA Analysis in Adrenocortical Carcinoma - A First Retrospective Cohort Study. ENDO 2025.
Jimenez C, Maple, S, Al-Sghir, F, Gagel,R. Pegvisomant and Tumor Volume Enlargement in Patient with Acromegaly. 8th International Pituitary Society Meeting.
Jimenez C, Cubb TD, MD, Skefos CM, MS, Goepfert RP, MD, Williams MD. Metastatic Paraganglioma With a Supraglottic Laryngeal Primary in a Patient With an SDHA Pathogenic Variant. ENDO 2025.
Jimenez C, Peter A, Tritos N, Carlsoson M, Villa G, Torre DL, Wajnrajch M, Cepedes L, Milller K. Disease-Specific Mortality in Patients With Acromeglay Treated With Pegvisomant -- An Acrostudy Analasis. ENDO 2025.
Lily Chen MD, MD PhD VB, Leonardo P Marcal MD, Camilo Jimenez MD, Jeena Varghese MD, Amishi Y Shah MD, Mouhammed Amir Habra MD, Matthew T Campbell MD. Gemcitabine oxaliplatin combination in Patients with Advanced Adrenocortical Carcinoma. ENDO 2025.
Chen L, Brondani VB, Marcal LP, Jimenez C, Varghese J, Shah AY, Habra MA, Campbell MT. Gemcitabine Oxaliplatin Combination in Patients with Advanced Adrenocortical Carcinoma. ENDO 2025.
Jimenez C, Waguespack S, Hosseini SM, Kaplan J. Paraganglioma in MEN2B Case Report. ENDO 2025.
Jimenez C. LITESPARK-015: Belzutifan in advanced pheochromocytoma and paraganglioma. ESMO 2025.
Zhang L, Tisserand G, Shen Y, Salehi M, Amar L, Cui Y, Œwi¹tkowska-Stodulska R, Moog S, Liu J, Gubbi S, Falhammar H, Kocjan T, Igaz P, Hadoux J, Young WF, Jr, Rem H, Babiñska A, Miguel VD, Beuschlein F, Liu L, Palmieri S, Jiang J, Fischer A, Varghese J, Carreira A, Parasiliti-Caprino M, Nölting S, Zhou Y, Prodanov T, Bancos I, Fassnacht M, Jimenez C, Alkaissi H, Tong A, Pacak K, Crona J. Safety of biopsy in phaeochromocytoma and paraganglioma: an international multicentre cohort study. European Congress of Endocrinology.

Book Chapters

Jimenez C, Libutti SK, Landry CS, Lloyd RV, Mckay RR, Rohren E, Seethala RR, Wang TS, Chen H, Perrier ND. Adrenal - Neuroendocrine Tumors. In: AJCC Cancer Staging Manual. 8th. Springer International Publishing, 919-926, 2017.
Gonzalez AR, Jimenez, P, Hyde S, Jessop AC, Jimenez C. Management of Locally Advanced and Metastatic Pheochromocytoma and Sympathetic Paraganglioma. In: Management of Adrenal Masses in Children and Adults. Springer international Publishing, 277-300, 2017.
Hu M, Jimenez C, Busaidy N, Habra M. Long Term and Late Effects of Survivorship: Endocrinological Issues. In: Advances in Cancer Survivorship Management, 343-360, 2015.
Hu M, Jimenez C, Cote G, Gagel R. Medullary Thyroid Carcinoma. In: Braverman/Werner & Ingbar's The Thyroid: A Fundamental and Clinical Text. 10th. Lippincott Williams & Wilkins, 2013.
Landry CS, Rich T, Jimenez C, Grubbs EG, Lee JE, Perrier ND. Multiple Endocrine Neoplasia. In: Neuroendocrine Tumors. Springer, 29-49, 2011.
Jimenez C, Gagel RF. Disorders Affecting Multiple Endocrine Systems. In: Harrison's Principles of Internal Medicine. 18th. McGraw Hill, 2011.
Jimenez C, Gagel RF. Multiple Endocrine Neoplasias and Autoimmune Endocrinopathies. In: Harrison's Endocrinology. Second. McGraww-Hill, 367-378, 2010.
Silberfein E, Jimenez C, Perrier N. Pheochromocytomas. In: Cameron, 2010.
Rich TA, Jimenez C, Evans DB. Hereditary Pheochromocytoma and Multiple Endocrine Neoplasia Type 2 (MEN2). In: Genetic Diagnosis of Endocrine Disorders, 2010.
Jimenez C, Gagel RF. Multiple Endocrine Neoplasia. In: Harrison's Hematology and Oncology. McGraw-Hill, 597-608, 2010.
Phan AT, Jimenez C. Adrenocortical Carcinoma. In: Neuro Endocrine Tumors, 2010.
Jimenez C. Neuroendocrinology. In: Neurology. 2. Manual Moderno, 391-403, 2010.
Rich T, Jimenez C, Evans D. Genetic Evaluation of Pheochromocytomas. Genetic Diagnosis of Endocrine Disorders. In: Endocrine Neoplasms, 2008.
Jimenez C, Gagel R. Disorders Affecting Multiple Endocrine Systems. In: Harrison's Principles of Internal Medicine. 17th. McGraw Hill, 2008.
Jimenez C. Thyroid Cancer. In: Medicina Interna (Internal Medicine). First. Colombian Association of Internal Medicine, 2006.
Jimenez C, Garavito G, Ramos P. Neuroendocrine Tumors of the Gastrointestinal Tract. In: Gastroenterología. Second, 2005.

Letters to the Editor

Jimenez C, Andreassen M, Berruti A. Belzutifan for Advanced Pheochromocytoma or Paraganglioma. Reply. N Engl J Med 394: 728, 2026.
Al-Ward, R, Waguespack, SG, Varghese, J, Lu, Y, Jimenez, C. Reply to the Letter to the Editor Concerning Metabolic and Pharmacological Interactions of 131I-MIBG. Clinical nuclear medicine 50: 1106-1107, 2025.

Less

CV information above last modified March 31, 2026

Camilo Jimenez, M.D.

About Dr. Camilo Jimenez

Present Title & Affiliation

Primary Appointment

Research Interests

Clinical Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Other Professional Positions

Intramural Institutional Committee Activities

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Other Articles

Abstracts

Book Chapters

Letters to the Editor

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Camilo Jimenez, M.D.

About Dr. Camilo Jimenez

Present Title & Affiliation

Primary Appointment

Research Interests

Clinical Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Other Professional Positions

Intramural Institutional Committee Activities

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Other Articles

Abstracts

Book Chapters

Letters to the Editor

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop UT MD Anderson